

CITATION REPORT

List of articles citing

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

DOI: [10.1038/nature10983](https://doi.org/10.1038/nature10983)

Nature, 2012, 486, 346-52.

Source: <https://exaly.com/paper-pdf/54314237/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2258	Abstract.		
2257	Bilateral hippocampal atrophy: consequences to verbal memory following temporal lobectomy. 2001 , 57, 597-604		35
2256	Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution. 2012 , 8, e1003027		18
2255	The handling and sampling of radical prostatectomy specimens for reporting and research: the Oxford approach. 2012 , 65, 1057-61		8
2254	How many diseases are colorectal cancer?. 2012 , 2012, 564741		20
2253	Expert opinion: future frontiers and challenges in cancer medicine. 2012 , 17, e3-5		2
2252	iBBiG: iterative binary bi-clustering of gene sets. 2012 , 28, 2484-92		33
2251	Disentanglement of the acute kidney injury syndrome. 2012 , 18, 579-84		10
2250	Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. 2012 , 4, 157ra143		277
2249	Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. 2012 , 22, 1995-2007		181
2248	PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer. 2012 , 3, 739-48		20
2247	Genome-based diagnostics and predictive tools: a new epoch for breast cancer management. 2012 , 8, 1211-4		
2246	Biomarkers in Breast Cancer - An Update. 2012 , 72, 819-832		25
2245	Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. 2012 , 12, 1245-8		8
2244	Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. 2012 , 8, 1152-5		13
2243	De novo mutations, protein-protein interactions and functional regulatory networks toward novel diagnostics in autism. 2012 , 9, 473-6		
2242	Major chromosomal breakpoint intervals in breast cancer co-localize with differentially methylated regions. 2012 , 2, 197		26

2241	Genome-scale technology driven advances to research into normal and malignant haematopoiesis. 2012 , 2012, 437956	
2240	Keeping an open mind: highlights and controversies of the breast cancer stem cell theory. 2012 , 4, 155-66	15
2239	A prooxidant mechanism for the anticancer and chemopreventive properties of plant polyphenols. 2012 , 13, 1738-49	105
2238	Profiling the immune stromal interface in breast cancer and its potential for clinical impact. 2012 , 7, 273-80	6
2237	Radiotherapy issues in elderly breast cancer patients. 2012 , 7, 453-9	11
2236	Auf Microarrays basierende Prognosefaktoren bei Brustkrebs. 2012 , 15, 43-45	
2235	Perspective: Not just for women. <i>Nature</i> , 2012 , 485, S66	50.4 2
2234	Medulloblastomics: the end of the beginning. 2012 , 12, 818-34	443
2233	Ten types of breast cancer?. 2012 , 380, 1212-3	2
2232	Molecular pathology of breast cancer: what a pathologist needs to know. 2012 , 138, 770-80	66
2231	Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. 2012 , 9, 599-614	23
2230	DrugLogit: logistic discrimination between drugs and nondrugs including disease-specificity by assigning probabilities based on molecular properties. 2012 , 52, 2165-80	33
2229	Editorial introductions. 2012 , 18, v-vi	
2228	New methods in mammary gland development and cancer: proteomics, epigenetics, symmetric division and metastasis. 2012 , 14, 314	1
2227	Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. 2012 , 14, 322	1
2226	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. 2012 , 14, R113	36
2225	Who's driving anyway? Herculean efforts to identify the drivers of breast cancer. 2012 , 14, 323	7
2224	ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR. 2012 , 14, R148	68

2223	Bioinformatics for cancer immunology and immunotherapy. 2012 , 61, 1885-903	32
2222	Zukünftige Entwicklung der gynäkologischen Onkologie. 2012 , 45, 678-683	
2221	Perspectives on systems biology applications in diabetic kidney disease. 2012 , 5, 491-508	26
2220	Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. 2012 , 14, 702-8	50
2219	CHAPTER 11:Breast Cancer ¶Importance of Life Stage with Respect to Environmental Influences. 2012 , 293-330	
2218	The rebel angel: mutant p53 as the driving oncogene in breast cancer. 2012 , 33, 2007-17	199
2217	What are we learning from the cancer genome?. 2012 , 9, 621-30	43
2216	Navigating cancer network attractors for tumor-specific therapy. 2012 , 30, 842-8	115
2215	TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer. 2012 , 3, 1055	76
2214	The evolving concept of cancer and metastasis stem cells. 2012 , 198, 281-93	299
2213	Evolution of the cancer genome. 2012 , 13, 795-806	424
2212	Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. 2012 , 72, 6414-24	87
2211	SnapShot: breast cancer. 2012 , 22, 562-562.e1	54
2210	Molecular characterisation of cell line models for triple-negative breast cancers. 2012 , 13, 619	60
2209	Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. 2012 , 13, 719	28
2208	Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer. 2012 , 12, 382	20
2207	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. 2012 , 5, 44	199
2206	Comprehensive molecular portraits of human breast tumours. <i>Nature</i> , 2012 , 490, 61-70	50.4 8025

2205	Breast cancer intratumor genetic heterogeneity: causes and implications. 2012 , 12, 1021-32	57
2204	Tackling cancer burden in the Middle East: Qatar as an example. 2012 , 13, e501-8	37
2203	Cancer heterogeneity: origins and implications for genetic association studies. 2012 , 28, 538-43	20
2202	Breast Cancer Heterogeneity: Need to Review Current Treatment Strategies. 2012 , 4, 225-231	2
2201	Gene signatures in breast cancer: current and future uses. 2012 , 5, 398-403	17
2200	Chromatin landscape and endocrine response in breast cancer. 2012 , 4, 675-83	12
2199	High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy. 2012 , 16, 235-40	3
2198	Mammographic screening debate on study design: a need to move the field forward. 2012 , 10, 164	4
2197	Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. 2012 , 192, 385-96	49
2196	DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. 2012 , 13, R124	156
2195	Calling sample mix-ups in cancer population studies. 2012 , 7, e41815	4
2194	Analysis of gene expression data from non-small cell lung carcinoma cell lines reveals distinct sub-classes from those identified at the phenotype level. 2012 , 7, e50253	2
2193	Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?. 2012 , 3, 202	3
2192	Identifying putative breast cancer-associated long intergenic non-coding RNA loci by high density SNP array analysis. 2012 , 3, 299	9
2191	Financial risk in commissioning: cancer costs. 2012 , 18, 315-324	3
2190	Is breast cancer staging obsolete?. 2012 , 19, 195-6	1
2189	Genomics: the breast cancer landscape. <i>Nature</i> , 2012 , 486, 328-9	50.4 30
2188	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. <i>Nature</i> , 2012 , 486, 395-9	50.4 1417

2187 Breast cancer: divide and conquer?. **2012**, 12, 375

2186 Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. **2013**, 8, 33 33

2185 Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. **2013**, 5, 29 70

2184 Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA. **2013**, 93, 224-35 30

2183 Emerging Concepts in Breast Cancer Risk Prediction. **2013**, 2, 43-52 6

2182 Phosphatase Modulators. **2013**, 3

2181 Cancer Genomics. **2013**, 4

2180 A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. **2013**, 140, 219-32 140

2179 Crowdsourced contest identifies best-in-class breast cancer prognostic. **2013**, 31, 578-80

2178 Next generation sequencing in cancer research and clinical application. **2013**, 15, 4 76

2177 Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrence. **2013**, 14, 102 19

2176 Detection of cancer before distant metastasis. **2013**, 13, 283 47

2175 Claudin 1 expression in basal-like breast cancer is related to patient age. **2013**, 13, 268 34

2174 Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. **2013**, 13, 175 36

2173 Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. **2013**, 13, 1 17

2172 Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. **2013**, 11, 52 111

2171 FiloDetect: automatic detection of filopodia from fluorescence microscopy images. **2013**, 7, 66 34

2170 Luminal breast cancer: from biology to treatment. **2013**, 10, 494-506 123

2169	A new genome-driven integrated classification of breast cancer and its implications. 2013 , 32, 617-28	212
2168	Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. 2013 , 24, 197-212	42
2167	A method for determining weights for excess relative risk and excess absolute risk when applied in the calculation of lifetime risk of cancer from radiation exposure. 2013 , 52, 135-45	13
2166	Cooperating transcription factors mediate the function of estrogen receptor. 2013 , 122, 1-12	12
2165	The complex genetic landscape of familial breast cancer. 2013 , 132, 845-63	94
2164	Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis. 2013 , 93, 701-10	21
2163	ROCK: a resource for integrative breast cancer data analysis. 2013 , 139, 907-21	27
2162	Array Comparative Genomic Hybridization. 2013 ,	1
2161	The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. 2013 , 24, 365-78	102
2160	FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. 2013 , 119, 191-419	115
2159	Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. 2013 , 3, 342-9	251
2158	Triple-negative breast cancer and the need for new therapeutic targets. 2013 , 183, 1064-1074	110
2157	MAST2 and NOTCH1 translocations in breast carcinoma and associated pre-invasive lesions. 2013 , 44, 2837-44	10
2156	Beyond BRCA1/2: polygenic, 'polyfunctional' molecular circuitry model to predict breast cancer risk. 2013 , 7, 675-8	2
2155	A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. 2013 , 7, 987-99	29
2154	Mutational analysis of breast cancer: guiding personalized treatments. 2013 , 22 Suppl 2, S19-21	12
2153	Pattern Recognition in Bioinformatics. 2013 ,	1
2152	Identification of stage-specific breast markers using quantitative proteomics. 2013 , 12, 5696-708	22

2151	Molecular pathways: PI3K pathway targets in triple-negative breast cancers. 2013 , 19, 3738-44	49
2150	Upregulated WAVE3 expression is essential for TGF- β -mediated EMT and metastasis of triple-negative breast cancer cells. 2013 , 142, 341-53	46
2149	Cell and Molecular Biology of Breast Cancer. 2013 ,	8
2148	Insights from mixture cure modeling of molecular markers for prognosis in breast cancer. 2013 , 31, 2047-54	17
2147	Carboxyl-terminal modulator protein positively regulates Akt phosphorylation and acts as an oncogenic driver in breast cancer. 2013 , 73, 6194-205	18
2146	Beyond GWASs: illuminating the dark road from association to function. 2013 , 93, 779-97	515
2145	Can we deconstruct cancer, one patient at a time?. 2013 , 29, 6-10	16
2144	From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. 2013 , 10, 1-6	60
2143	Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest. 2013 , 22, 2451-61	14
2142	RNA sequencing of cancer reveals novel splicing alterations. 2013 , 3, 1689	134
2141	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. 2013 , 93, 1046-60	80
2140	Progesterone/RANKL is a major regulatory axis in the human breast. 2013 , 5, 182ra55	131
2139	The molecular diversity of Luminal A breast tumors. 2013 , 141, 409-20	90
2138	Hypoxia-induced signaling and its relevance in discovering biomarkers for cancer research. 2013 , 5, 135-141	2
2137	Genetic susceptibility to triple-negative breast cancer. 2013 , 73, 2025-30	141
2136	Video Q&A: molecular profiling of breast cancer. 2013 , 11, 150	
2135	A robust prognostic signature for hormone-positive node-negative breast cancer. 2013 , 5, 92	17
2134	Integration of Gene Signatures and Genomic Data into Radiation Oncology Practice. 2013 , 29-46	

2133	PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. 2013 , 11, 245	23
2132	Pathway-based outlier method reveals heterogeneous genomic structure of autism in blood transcriptome. 2013 , 6, 34	20
2131	Striking life events associated with primary breast cancer susceptibility in women: a meta-analysis study. 2013 , 32, 53	30
2130	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. 2013 , 138, 899-908	18
2129	Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. 2013 , 15, R115	14
2128	Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. 2013 , 6, 54	27
2127	Insulin and IGFs in obesity-related breast cancer. 2013 , 18, 277-89	63
2126	Biomarkers of Therapeutic Resistance in Breast Cancer. 2013 , 5, 275-283	
2125	Genomic profiling of histological special types of breast cancer. 2013 , 142, 257-69	55
2124	BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. 2013 , 15, R52	105
2123	Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer. 2013 , 14, 5-8	3
2122	Dissecting cancer heterogeneity--an unsupervised classification approach. 2013 , 45, 2574-9	18
2121	Selective nucleic acid removal via exclusion (SNARE): capturing mRNA and DNA from a single sample. 2013 , 85, 9764-70	33
2120	A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. 2013 , 24, 182-96	114
2119	Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels. 2013 , 92, 247-56	33
2118	The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. 2013 , 39, 11-26	554
2117	Weighing in on autoimmune disease: 'Hub-and-spoke' T cell traffic in autoimmunity. 2013 , 19, 139-41	10
2116	Next-generation sequencing in cancer research & diagnostics. 2013 , 20-40	

2115	AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. 2013 , 12, 2356-66	34
2114	Molecular fingerprinting catches responders to therapeutic agents. 2013 , 14, 135	
2113	Needles in a haystack: finding recurrent genomic changes in breast cancer. 2013 , 14, 304	2
2112	The genomic map of breast cancer: which roads lead to better targeted therapies?. 2013 , 15, 209	10
2111	Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. 2013 , 73, 6757-69	35
2110	Pattern discovery and cancer gene identification in integrated cancer genomic data. 2013 , 110, 4245-50	250
2109	A Nonparametric Bayesian Model for Local Clustering with Application to Proteomics. 2013 , 108,	16
2108	KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. 2013 , 5, 169ra12	58
2107	Clinical opportunities and challenges in targeting tumour dormancy. 2013 , 10, 41-51	52
2106	Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. 2013 , 32, 3184-97	43
2105	Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer. 2013 , 137, 837-47	16
2104	The genomic landscape of breast cancer as a therapeutic roadmap. 2013 , 3, 27-34	161
2103	RUNX2 in mammary gland development and breast cancer. 2013 , 228, 1137-42	55
2102	Predicting outcomes in radiation oncology--multifactorial decision support systems. 2013 , 10, 27-40	270
2101	Cancer genetics and genomics of human FOX family genes. 2013 , 328, 198-206	251
2100	Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. 2013 , 137, 407-16	22
2099	Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. 2013 , 3, 182-97	90
2098	Long-range transcriptional regulation of breast cancer genes. 2013 , 52, 113-25	5

2097	Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. 2013 , 152, 633-41	255
2096	Innovation requires a new regulatory framework to improve research and development of new medical therapies. 2013 , 2, 178-180	3
2095	Tumour selective targeting of cell cycle kinases for cancer treatment. 2013 , 13, 529-35	51
2094	Breast pathology. 2013 , 31, 4-10	
2093	Current controversies in breast cancer: do we have the answers?. 2013 , 25, 77-9	
2092	Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. 2013 , 25, 109-16	33
2091	Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. 2013 , 132, 2044-55	9
2090	Tackling the diversity of triple-negative breast cancer. 2013 , 19, 6380-8	120
2089	Novel insights into breast cancer genetic variance through RNA sequencing. 2013 , 3, 2256	46
2088	A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes: Haibe-Kains B, Desmedt C, Loi S, et al (Dana-Farber Cancer Inst, Boston, MA; UniversitLibre de Bruxelles, Brussels, Belgium) J Natl Cancer Inst 104:311-325, 2012. 2013 , 24, 36-38	
2087	Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. 2013 , 587, 3327-34	20
2086	Functional analysis-make or break for cancer predictability. 2013 , 743-744, 132-141	4
2085	Activation of NFkB is a novel mechanism of pro-survival activity of glucocorticoids in breast cancer cells. 2013 , 337, 90-5	33
2084	Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems. 2013 , 78, 568-75	36
2083	Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens. 2013 , 25, 80-92	9
2082	Energy management - a critical role in cancer induction?. 2013 , 88, 198-217	12
2081	Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. 2013 , 13, 205-8	3
2080	Breast cancer: Tamoxifen--when more might be better. 2013 , 10, 125-6	3

2079	Weighing in on autoimmune disease: Big data tip the scale. 2013 , 19, 138-9	7
2078	The cancer biology of whole-chromosome instability. 2013 , 32, 4727-36	90
2077	Finding common regions of alteration in copy number data. 2013 , 973, 339-53	
2076	Distinguishing somatic and germline copy number events in cancer patient DNA hybridized to whole-genome SNP genotyping arrays. 2013 , 973, 355-72	5
2075	Analysis of circulating tumor DNA to monitor metastatic breast cancer. 2013 , 368, 1199-209	1560
2074	Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. 2013 , 110, E1026-34	208
2073	Translating genomics to the clinic: implications of cancer heterogeneity. 2013 , 59, 127-37	20
2072	The implications of clonal genome evolution for cancer medicine. 2013 , 368, 842-51	275
2071	FOXA1 mutations in hormone-dependent cancers. 2013 , 3, 20	42
2070	The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. 2013 , 12, 1166-79	126
2069	Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. 2013 , 13, 1595-607	22
2068	Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. 2013 , 13, 151-65	36
2067	Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome. 2013 , 138, 485-97	8
2066	The shaping and functional consequences of the microRNA landscape in breast cancer. <i>Nature</i> , 2013 , 497, 378-82	50.4 321
2065	Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. 2013 , 14, 665-78	132
2064	Translating next generation sequencing to practice: opportunities and necessary steps. 2013 , 7, 743-55	28
2063	Hide and seek: tell-tale signs of breast cancer lurking in the blood. 2013 , 32, 289-302	13
2062	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. 2013 , 10, 377-89	146

2061	New Microtubule Inhibitors in Breast Cancer. 2013 , 5, 1-10	3
2060	Molecular and clinicopathological markers of prognosis in breast cancer. 2013 , 13, 481-98	4
2059	Genetic heterogeneity in breast cancer: the road to personalized medicine?. 2013 , 11, 151	42
2058	Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. 2013 , 24, 120-9	211
2057	Protein phosphatase 2A: a target for anticancer therapy. 2013 , 14, e229-38	283
2056	Reimagining psychoses: an agnostic approach to diagnosis. 2013 , 146, 10-6	61
2055	High-throughput gene expression and mutation profiling: current methods and future perspectives. 2013 , 8, 401-6	11
2054	The practicalities of using tissue slices as preclinical organotypic breast cancer models. 2013 , 66, 253-5	43
2053	Personalizing health care: feasibility and future implications. 2013 , 11, 179	63
2052	Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. 2013 , 138, 215-23	19
2051	Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression. 2013 , 73, 6913-25	32
2050	TCGA Toolbox. 2013 ,	1
2049	Integrating NGS and third-generation sequencing technologies into clinical genomic medicine. 2013 , 6-18	
2048	FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. 2013 , 340, 104-12	73
2047	Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. 2013 , 34, 2300-8	228
2046	Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. 2013 , 71, 153-63	22
2045	A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. 2013 , 19, 2061-70	46
2044	8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. 2013 , 5, 339-57	11

2043	Mapping of three genetic determinants of susceptibility to estrogen-induced mammary cancer within the Emca8 locus on rat chromosome 5. 2013 , 6, 59-69	15
2042	Ontology-aware classification of tissue and cell-type signals in gene expression profiles across platforms and technologies. 2013 , 29, 3036-44	21
2041	Master regulators of FGFR2 signalling and breast cancer risk. 2013 , 4, 2464	128
2040	[Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting]. 2013 , 100, 1295-310	3
2039	Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer. 2013 , 13, 1-4	8
2038	SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. 2013 , 27, 274-87	33
2037	CancerDR: cancer drug resistance database. 2013 , 3, 1445	79
2036	Brain neoplasms and coagulation. 2013 , 39, 881-95	27
2035	A self-updating road map of The Cancer Genome Atlas. 2013 , 29, 1333-40	29
2034	Improving breast cancer survival analysis through competition-based multidimensional modeling. 2013 , 9, e1003047	57
2033	An evolutionary perspective on anti-tumor immunity. 2012 , 2, 202	12
2032	Biomolecular events in cancer revealed by attractor metagenes. 2013 , 9, e1002920	78
2031	Bayesian consensus clustering. 2013 , 29, 2610-6	136
2030	Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. 2013 , 24, 1956-7	17
2029	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. 2013 , 9, e1003212	209
2028	Integrative analysis of cancer-related signaling pathways. 2013 , 4, 124	9
2027	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. 2013 , 7, 1-19	8
2026	Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. 2013 , 2013, 973584	40

2025	MicroRNAs and triple negative breast cancer. 2013 , 14, 22202-20	59
2024	Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. 2013 , 86, 20120601	74
2023	Reply to A.-S. Dieudonné et al and J.M. Rae et al. 2013 , 31, 2755-6	3
2022	Going with the flow: from circulating tumor cells to DNA. 2013 , 5, 207ps14	90
2021	CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. 2013 , 31, 2753-5	6
2020	Prediction of response to anticancer immunotherapy using gene signatures. 2013 , 31, 2369-71	40
2019	Advances in the treatment of luminal breast cancer. 2013 , 25, 49-54	13
2018	Personalized medicine for metastatic breast cancer. 2013 , 25, 615-24	4
2017	Current world literature. 2013 , 25, 81-9	
2016	Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?. 2013 , 23, 423-5	3
2015	Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. 2013 , 45, 629-36	8
2014	Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy. 2013 , 12, 2705-6	10
2013	Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer. 2013 , 19, 1411-21	41
2012	Pak1 kinase links ErbB2 to E-catenin in transformation of breast epithelial cells. 2013 , 73, 3671-82	61
2011	Next-Generation Sequencing & Molecular Diagnostics. 2013 ,	1
2010	Molecular Profiling of Immunotherapeutic Resistance. 2013 , 373-394	2
2009	Clinical relevance of miRNAs in cancer. 2013 , 42-62	
2008	Progression of Early Breast Cancer to an Invasive Phenotype. 2013 , 143-159	0

2007	Breast Cancer Genomics: From Portraits to Landscapes. 2013 , 255-294	
2006	Gene expression 'signature' limitations and genome architecture-based perspectives for robust cancer biomarkers. 2013 , 7, 79-82	1
2005	Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma. 2013 , 12, 759-67	18
2004	TriageTools: tools for partitioning and prioritizing analysis of high-throughput sequencing data. 2013 , 41, e86	5
2003	Precise inference of copy number alterations in tumor samples from SNP arrays. 2013 , 29, 2964-70	9
2002	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. 2013 , 110, E1301-10	58
2001	Circulating tumour cells: insights into tumour heterogeneity. 2013 , 274, 137-43	37
2000	An Integrative Genomics Approach for Associating GWAS Information with Triple-Negative Breast Cancer. 2013 , 12, 1-20	14
1999	Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. 2013 , 73, 3470-80	289
1998	Genomic compartmentalization of gene families encoding core components of metazoan signaling systems. 2013 , 56, 215-25	2
1997	Combat or surveillance? Evaluation of the heterogeneous inflammatory breast cancer microenvironment. 2013 , 229, 569-78	20
1996	The 11q13-q14 amplicon: clinicopathological correlations and potential drivers. 2013 , 52, 333-55	49
1995	High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. 2013 , 2, 437-46	33
1994	Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. 2013 , 31, 131-61	35
1993	Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. 2013 , 5, 181re1	94
1992	Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. 2013 , 13, 5-8	10
1991	Genome evolution during progression to breast cancer. 2013 , 23, 1097-108	86
1990	The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. 2013 , 12, 2371-5	29

1989	Phosphatidylinositol-4-phosphate: the Golgi and beyond. 2013 , 35, 612-22	84
1988	The mutational landscape of phosphorylation signaling in cancer. 2013 , 3, 2651	116
1987	Drugs, non-drugs, and disease category specificity: organ effects by ligand pharmacology. 2013 , 24, 319-31	8
1986	Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. 2013 , 109, 2453-61	5
1985	Redox cycling of endogenous copper by thymoquinone leads to ROS-mediated DNA breakage and consequent cell death: putative anticancer mechanism of antioxidants. 2013 , 4, e660	71
1984	Genomic medicine frontier in human solid tumors: prospects and challenges. 2013 , 31, 1874-84	90
1983	CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. 2013 , 109, 2412-23	97
1982	DREAM team. 2013 , 6, 430-430	
1981	Triple-negative breast cancer: molecular characterization and targeted therapies. 2013 , 2, 417-430	1
1980	Diagnostic perspectives in the epoch of next-generation sequencing. 2013 , 98-111	
1979	Roles of p53 and p16 in triple-negative breast cancer. 2013 , 2, 537-544	11
1978	Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. 2013 , 110, 7413-7	128
1977	Incorporating genomics into breast cancer clinical trials and care. 2013 , 19, 6371-9	14
1976	Development of a prognostic model for breast cancer survival in an open challenge environment. 2013 , 5, 181ra50	91
1975	Tight Junctions in Cancer Metastasis. 2013 ,	3
1974	Genome function, ChIP-Seq and personalized diagnostics. 2013 , 78-96	
1973	Comprehensive whole genome and transcriptome analysis for novel diagnostics. 2013 , 64-76	
1972	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. 2013 , 3, 3544	42

1971	Emerging treatments for metastatic breast cancer: update from 2012. 2013 , 2, 33-45	
1970	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. 2013 , 15, R97	13
1969	ELF5, normal mammary development and the heterogeneous phenotypes of breast cancer. 2013 , 2, 489-498	6
1968	Locoregional recurrence of breast cancer. 2013 , 389-408	
1967	A decision-theoretic approach for segmental classification. 2013 , 7,	9
1966	Modeling precision treatment of breast cancer. 2013 , 14, R110	204
1965	Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. 2013 , 6, 839-52	70
1964	Changing concepts of cancer stem cells and their application into targeted therapy for cancer. 2013 , 56, 611	1
1963	Cell cycle, checkpoints and cancer. 2013 ,	
1962	Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence. 2013 , 8, e53850	17
1961	A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. 2013 , 8, e54979	4
1960	Simple and versatile molecular method of copy-number measurement using cloned competitors. 2013 , 8, e69414	7
1959	Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma. 2013 , 8, e70790	9
1958	Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition. 2013 , 8, e77553	40
1957	An integrated model of the transcriptome of HER2-positive breast cancer. 2013 , 8, e79298	16
1956	Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. 2013 , 4, 21	129
1955	Evaluation of calling algorithms for array-CGH. 2013 , 4, 217	10
1954	Personalized cancer care conference. 2013 , 3, 70-81	3

1953	Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. 2013 , 4, 1868-81	64
1952	Role of obesity in the risk of breast cancer: lessons from anthropometry. 2013 , 2013, 906495	66
1951	A gradient boosting algorithm for survival analysis via direct optimization of concordance index. 2013 , 2013, 873595	37
1950	Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. 2013 , 2013, 219869	12
1949	Translating complex genomic discoveries into molecular diagnostic tests. 2013 , 2-5	
1948	Adjuvant chemotherapy: which patient? What regimen?. 2013 , 3-8	3
1947	Molecular profiling and the reclassification of cancer: divide and conquer. 2013 , 127-34	20
1946	PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. 2014 , 61, 461-7	11
1945	Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. 2014 , 9, e88401	27
1944	DACH1: its role as a classifier of long term good prognosis in luminal breast cancer. 2014 , 9, e84428	19
1943	A microRNA signature associated with early recurrence in breast cancer. 2014 , 9, e91884	64
1942	Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma. 2014 , 9, e98653	4
1941	Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer. 2014 , 9, e104282	18
1940	A meta-analysis of multiple matched copy number and transcriptomics data sets for inferring gene regulatory relationships. 2014 , 9, e105522	5
1939	Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis. 2014 , 9, e112541	58
1938	Mining CK2 in cancer. 2014 , 9, e115609	98
1937	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. 2014 , 3, e01763	75
1936	Evidence for a Functional Link between Chromosomal Breakpoints and Aberrant DNA Methylation in Cancer. 2014 , 4, 46	4

1935	Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. 2014 , 6, 81-91	18
1934	Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients. 2014 , 17, 1-7	10
1933	Biobanking shifts to "precision medicine". 2014 , 11	1
1932	Insights into the next generation of cancer stem cell research. 2014 , 19, 1015-27	6
1931	Rad51 supports triple negative breast cancer metastasis. 2014 , 5, 3261-72	64
1930	Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. 2014 , 10, 52-63	70
1929	Subtyping of breast cancer using reverse phase protein arrays. 2014 , 11, 757-70	13
1928	Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. 2014 , 26, 562-7	13
1927	A framework for biobank sustainability. 2014 , 12, 60-8	83
1926	Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. 2014 , 74, 3344-56	22
1925	A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. 2014 , 15, 473	52
1924	Cancer genomics just got personal. 2014 , 15, 464	2
1923	Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. 2014 , 3, e100	45
1922	Through a glass darkly: economics and personalised medicine. 2014 , 32, 1055-61	12
1921	Genome-driven integrated classification of breast cancer validated in over 7,500 samples. 2014 , 15, 431	130
1920	A framework for generalized subspace pattern mining in high-dimensional datasets. 2014 , 15, 355	2
1919	JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK2 inhibitors. 2014 , 2, 301-6	17
1918	Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. 2014 , 15, 876	19

1917	Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. 2014 , 23, 2311-21	21
1916	Genome-based approaches for the diagnosis of breast cancer: a review with perspective. 2014 , 3, 173-193	
1915	A systems biology approach identifies effective tumor-stroma common targets for oral squamous cell carcinoma. 2014 , 74, 2306-15	23
1914	JNK suppresses tumor formation via a gene-expression program mediated by ATF2. 2014 , 9, 1361-74	29
1913	An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. 2014 , 33, 2478-86	26
1912	The AURORA initiative for metastatic breast cancer. 2014 , 111, 1881-7	68
1911	Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth. 2014 , 15, 1013-28	11
1910	MicroRNA Expression Profiling and Its Clinical Impact in Breast Cancer. 2014 , 355-367	2
1909	Generalized species sampling priors with latent Beta reinforcements. 2014 , 109, 1466-1480	27
1908	Comparisons of non-Gaussian statistical models in DNA methylation analysis. 2014 , 15, 10835-54	3
1907	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. 2014 , 7, 203-15	69
1906	Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. 2014 , 106,	34
1905	Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. 2014 , 16, 982-91	30
1904	Tug of war between survival and death: exploring ATM function in cancer. 2014 , 15, 5388-409	23
1903	Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. 2014 , 10, e1003409	35
1902	Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells. 2014 , 10, e1004646	15
1901	Inferring clonal composition from multiple sections of a breast cancer. 2014 , 10, e1003703	84
1900	Single nucleotide variants in transcription factors associate more tightly with phenotype than with gene expression. 2014 , 10, e1004325	9

1899	Variable selection for generalized canonical correlation analysis. 2014 , 15, 569-83	104
1898	Integrative omics analysis. A study based on Plasmodium falciparum mRNA and protein data. 2014 , 8 Suppl 2, S4	12
1897	Regulation of Ras localization and cell transformation by evolutionarily conserved palmitoyltransferases. 2014 , 34, 374-85	21
1896	A new method for predicting patient survivorship using efficient bayesian network learning. 2014 , 13, 47-57	10
1895	'Personalized medicine': what's in a name?. 2014 , 11, 197-210	59
1894	Therapeutic targeting of integrin $\alpha 5 \beta 1$ in breast cancer. 2014 , 106,	89
1893	Integrated microarray analytics for the discovery of gene signatures for triple-negative breast cancer. 2014 ,	1
1892	Construction of a business model to assure financial sustainability of biobanks. 2014 , 12, 389-94	14
1891	Chromosome-breakage genomic instability and chromothripsis in breast cancer. 2014 , 15, 579	37
1890	The prognostic ease and difficulty of invasive breast carcinoma. 2014 , 9, 129-142	46
1889	MultiBLUP: improved SNP-based prediction for complex traits. 2014 , 24, 1550-7	175
1888	Systems consequences of amplicon formation in human breast cancer. 2014 , 24, 1559-71	21
1887	Linking signaling pathways to transcriptional programs in breast cancer. 2014 , 24, 1869-80	44
1886	The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. 2014 , 9, 1318-32	15
1885	Distinct Copy Number, Coding Sequence, and Locus Methylation Patterns Underlie Rhg1-Mediated Soybean Resistance to Soybean Cyst Nematode. 2014 , 165, 630-647	90
1884	New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors. 2014 , 20, 6242-6	13
1883	Breast cancer subtype identification using machine learning techniques. 2014 ,	1
1882	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. 2014 , 106,	132

1881	Whole-genome multiparametric screening to identify modulators of epithelial-to-mesenchymal transition. 2014 , 12, 385-94	5
1880	Molecular pathology and prostate cancer therapeutics: from biology to bedside. 2014 , 232, 178-84	26
1879	Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. 2014 , 32, 3848-57	58
1878	A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. 2014 , 16, 467	11
1877	Integration of genomic data enables selective discovery of breast cancer drivers. 2014 , 159, 1461-75	67
1876	Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study. 2014 , 135, 669-81	12
1875	Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer. 2014 , 13, 2104-15	41
1874	Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. 2014 , 184, 3217-25	35
1873	Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition. 2014 , 6, 93-106	12
1872	MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. 2014 , 111, 17606-11	46
1871	Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. 2014 , 23, 1464-83	51
1870	HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy. 2014 , 106,	5
1869	The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis. 2014 , 127, 4740-9	20
1868	A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. 2014 , 10, 744	96
1867	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. 2014 , 101, 925-38	30
1866	DNA hypomethylation in plasma as a cancer biomarker: when less is more?. 2014 , 14, 419-22	0
1865	Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. 2014 , 74, 7406-17	30
1864	Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. 2014 , 56, 617-29	105

1863	Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 2014 , 289, 34189-204	51
1862	Lessons learned in breast cancer surgery. 2014 , 101, 145-7	1
1861	Genome network medicine: innovation to overcome huge challenges in cancer therapy. 2014 , 6, 201-8	6
1860	Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations. 2014 , 16, R71	6
1859	An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor- β in human breast cancer. 2014 , 16, R57	17
1858	Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. 2014 , 16, R46	30
1857	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. 2014 , 15, R9	51
1856	Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. 2014 , 9, e115346	13
1855	Breast cancer prognostic biomarker using attractor metagenes and the FGD3-SUSD3 metagene. 2014 , 23, 2850-6	15
1854	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. 2014 , 42, 6106-27	53
1853	Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. 2014 , 14, 762	11
1852	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. 2014 , 14, 908	33
1851	Cancer progression modeling using static sample data. 2014 , 15, 440	18
1850	The multitude of molecular analyses in cancer: the opening of Pandora's box. 2014 , 15, 447	6
1849	A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. 2014 , 6, 105	76
1848	A systems biology approach to identify proliferative biomarkers and pathways in breast cancer. 2014 ,	0
1847	The mammary cellular hierarchy and breast cancer. 2014 , 71, 4301-24	40
1846	Approaches to uncovering cancer diagnostic and prognostic molecular signatures. 2014 , 1, e957981	1

1845	Sequencing efforts help to refine the molecular classification of breast cancer. 2014 , 26, 18-20	
1844	TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. 2014 , 20, 3569-80	167
1843	Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. 2014 , 9, e88309	63
1842	Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. 2014 , 14, 1385-9	11
1841	IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers. 2014 , 74, 4908-21	25
1840	Taxonomy of breast cancer based on normal cell phenotype predicts outcome. 2014 , 124, 859-70	134
1839	Complexities of androgen receptor signalling in breast cancer. 2014 , 21, T161-81	95
1838	Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer. 2014 , 106,	26
1837	SIP1/NHERF2 enhances estrogen receptor alpha transactivation in breast cancer cells. 2014 , 42, 6885-900	15
1836	Theranostic and molecular classification of breast cancer. 2014 , 138, 44-56	35
1835	A pathway-based data integration framework for prediction of disease progression. 2014 , 30, 838-45	52
1834	The effects of variations in genomic modules on breast cancer phenotype. 2014 , 18, 296-303	
1833	Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study. 2014 , 147, 639-51	37
1832	Omics Approaches in Breast Cancer. 2014 ,	8
1831	Breast Cancer Genomics. 2014 , 53-103	
1830	The lipid kinase PI4KIII β is highly expressed in breast tumors and activates Akt in cooperation with Rab11a. 2014 , 12, 1492-508	17
1829	Human breast cancer metastases to the brain display GABAergic properties in the neural niche. 2014 , 111, 984-9	185
1828	Core symptom measures in cancer clinical trials. 2014 , 106,	

1827	Brain neoplasms and coagulation-lessons from heterogeneity. 2014 , 5, e0030	8
1826	Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. 2014 , 19, 1076-83	85
1825	Multidrug-resistant breast cancer: current perspectives. 2014 , 6, 1-13	61
1824	Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells. 2014 , 16, R60	14
1823	Initial experience with genomic profiling of heavily pretreated breast cancers. 2014 , 21, 3216-22	3
1822	Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?. 2014 , 26, 21-6	1
1821	Individualizing breast cancer treatment-The dawn of personalized medicine. 2014 , 320, 1-11	24
1820	Breast cancer prognosis predicted by nuclear receptor-coregulator networks. 2014 , 8, 998-1013	14
1819	The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors. 2014 , 8, 273-84	21
1818	N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients. 2014 , 68, 185-9	9
1817	The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response. 2014 , 24, 114-9	20
1816	The '-omics' revolution and oesophageal adenocarcinoma. 2014 , 11, 19-27	25
1815	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. 2014 , 16, 386-94	14
1814	Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. 2014 , 31, 33-45	38
1813	Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. 2014 , 143, 301-12	43
1812	The role of genes co-amplified with nicastrin in breast invasive carcinoma. 2014 , 143, 393-401	5
1811	Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. 2014 , 143, 57-68	25
1810	The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. 2014 , 53, 806-18	43

1809	MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?. 2014 , 20, 670-87	25
1808	Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. 2014 , 144, 273-85	14
1807	Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. 2014 , 2, 3	50
1806	Molecular tests as prognostic factors in breast cancer. 2014 , 464, 283-91	30
1805	EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration. 2014 , 232, 391-404	38
1804	Second-Generation Sequencing for Cancer Genome Analysis. 2014 , 13-30	1
1803	Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. 2014 , 33, 4767-77	51
1802	Principles and methods of integrative genomic analyses in cancer. 2014 , 14, 299-313	245
1801	MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. 2014 , 233, 368-79	89
1800	The challenge of intratumour heterogeneity in precision medicine. 2014 , 276, 41-51	50
1799	Cancer Transcriptome Sequencing and Analysis. 2014 , 31-47	1
1798	HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. 2014 , 145, 193-203	29
1797	Proteomic analysis of tissue samples in translational breast cancer research. 2014 , 11, 285-302	11
1796	Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling. 2014 , 289, 1164-73	28
1795	TP53 mutations in human cancer: database reassessment and prospects for the next decade. 2014 , 35, 672-88	191
1794	Novel roles for ERK5 and cofilin as critical mediators linking ER α -driven transcription, actin reorganization, and invasiveness in breast cancer. 2014 , 12, 714-27	48
1793	Metastatic progression of breast cancer: insights from 50 years of autopsies. 2014 , 232, 23-31	112
1792	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. 2014 , 232, 274-82	40

1791	Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. 2014 , 35, 766-78	25
1790	Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. 2014 , 6, 88-100	29
1789	Biomarkers of drugs targeting HER-family signalling in cancer. 2014 , 232, 219-29	47
1788	Targeting Akt3 signaling in triple-negative breast cancer. 2014 , 74, 964-73	109
1787	Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes. 2014 , 23, 5378-93	27
1786	Blind Source Separation. 2014 ,	35
1785	Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. 2014 , 11, 149-55	145
1784	Colon resection: is standard technique adequate?. 2014 , 23, 25-34	4
1783	Genomics meets proteomics: identifying the culprits in disease. 2014 , 133, 689-700	16
1782	Clonal analysis via barcoding reveals diverse growth and differentiation of transplanted mouse and human mammary stem cells. 2014 , 14, 253-63	46
1781	Rapid learning for precision oncology. 2014 , 11, 109-18	64
1780	Breast Cancer Genomics. 2014 , 213-232	2
1779	Lobular breast cancer: pathology, biology, and options for clinical intervention. 2014 , 62, 7-21	15
1778	Molecularly targeted cancer therapy: some lessons from the past decade. 2014 , 35, 41-50	206
1777	GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). 2014 , 289, 24102-13	42
1776	MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development. 2014 , 74, 6648-60	58
1775	Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. 2014 , 74, 5045-56	77
1774	miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. 2014 , 8, 1690-702	58

1773	Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome. 2014 , 148, 41-59	31
1772	Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. 2014 , 5, 5073	42
1771	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. 2014 , 5, 5203	164
1770	Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase β but not α inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation. 2014 , 50, 5388-90	21
1769	NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. 2014 , 74, 3935-46	65
1768	A data standard for sourcing fit-for-purpose biological samples in an integrated virtual network of biobanks. 2014 , 12, 184-91	21
1767	MicroRNAs: Key Regulators of Oncogenesis. 2014 ,	10
1766	Bias correction for selecting the minimal-error classifier from many machine learning models. 2014 , 30, 3152-8	17
1765	The kinome associated with estrogen receptor-positive status in human breast cancer. 2014 , 21, R357-70	4
1764	BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. 2014 , 74, 6161-72	43
1763	Chemical biology approaches to target validation in cancer. 2014 , 17, 87-100	30
1762	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). 2014 , 111, 1060-4	22
1761	Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. 2014 , 32, 2794-803	197
1760	Similarity network fusion for aggregating data types on a genomic scale. 2014 , 11, 333-7	849
1759	Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine?. 2014 , 14, 853-69	19
1758	Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. 2014 , 7, 114-27	113
1757	Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. 2014 , 74, 2936-45	51
1756	Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. 2014 , 5, 405-13	99

1755	Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. 2014 , 158, 1199-1209	167
1754	A diagnostic illusory? The case of distinguishing between "vegetative" and "minimally conscious" states. 2014 , 116, 134-41	24
1753	Rare-variant association analysis: study designs and statistical tests. 2014 , 95, 5-23	596
1752	Clonal evolution in breast cancer revealed by single nucleus genome sequencing. <i>Nature</i> , 2014 , 512, 155-604	730
1751	Integrating germline and somatic data towards a personalized cancer medicine. 2014 , 20, 413-5	9
1750	An update on the medical management of breast cancer. 2014 , 348, g3608	46
1749	Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression. 2014 , 110, 715-23	22
1748	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. 2014 , 111, 1532-41	82
1747	Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. 2014 , 19, 805-13	93
1746	Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. 2014 , 20, 4827-36	150
1745	Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. 2014 , 15, 170	19
1744	Functional characterization of breast cancer using pathway profiles. 2014 , 7, 45	8
1743	Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. 2014 , 3, 417	23
1742	The molecular landscape of the normal human breast--defining normal. 2014 , 16, 102	
1741	A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions. 2014 , 15, R71	25
1740	Molecular classification of infiltrating breast cancer: toward personalized therapy. 2014 , 34, 1178-95	51
1739	Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. 2014 , 146, 309-20	10
1738	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. 2014 , 147, 227-35	16

1737	Back to the basis: breast cancer heterogeneity from an etiological perspective. 2014 , 106,	3
1736	How many etiological subtypes of breast cancer: two, three, four, or more?. 2014 , 106,	142
1735	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. 2014 , 4, 4999	87
1734	Einsatz von Genhybridisierungstests und DNA-Sequenzierung bei metastasiertem Mammakarzinom. 2014 , 20, 778-779	
1733	Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. 2014 , 146, 25-40	20
1732	Nuclear CSPP1 expression defined subtypes of basal-like breast cancer. 2014 , 111, 326-38	7
1731	Metabolic transformations in breast cancer subtypes. 2014 , 2,	3
1730	Profiling metabolic changes in breast cancer with targeted proteomics. 2014 , 2,	1
1729	JARID1B is a luminal lineage-driving oncogene in breast cancer. 2014 , 25, 762-77	131
1728	UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. 2014 , 74, 1705-17	155
1727	Can We Predict Response and/or Resistance to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer?. 2014 , 10, 164-172	2
1726	Nucleosome positioning and histone modifications define relationships between regulatory elements and nearby gene expression in breast epithelial cells. 2014 , 15, 331	33
1725	Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. 2014 , 14, 211	27
1724	Advances in the approach to novel drug clinical development for breast cancer. 2014 , 9, 647-68	5
1723	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. 2014 , 8, 1588-602	38
1722	An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. 2014 , 46, 1051-9	158
1721	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. 2014 , 40, 1089-95	19
1720	Metastatic breast cancer subtypes and central nervous system metastases. 2014 , 23, 623-8	64

1719	Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. 2014 , 91, 436-46	27
1718	Using high-throughput transcriptomic data for prognosis: a critical overview and perspectives. 2014 , 74, 4612-21	38
1717	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). 2014 , 15, 267-74	282
1716	Mammary stem cells and the differentiation hierarchy: current status and perspectives. 2014 , 28, 1143-58	375
1715	A community effort to assess and improve drug sensitivity prediction algorithms. 2014 , 32, 1202-12	447
1714	SAFIR01: steps towards precision treatment in breast cancer. 2014 , 15, 242-3	8
1713	The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. 2014 , 6, 141-54	43
1712	DNA polymerase β deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. 2014 , 8, 520-32	27
1711	Towards individualized cancer therapy: Challenges and prospects. 2014 , 8, 1-8	5
1710	Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. 2014 , 190, 203-9	6
1709	Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. 2014 , 8, 1326-38	77
1708	KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. 2014 , 16, 247-56, 256.e2	54
1707	Big data bioinformatics. 2014 , 229, 1896-900	109
1706	The omics of triple-negative breast cancers. 2014 , 60, 122-33	44
1705	Molecular classification of breast cancer. 2014 , 465, 1-14	106
1704	Molecular profiling of male breast cancer - lost in translation?. 2014 , 53, 526-35	28
1703	Stratified medicine approaches for the treatment of musculoskeletal disorders. 2014 , 16, 127-32	5
1702	The protein phosphatase 2A regulatory subunit B55 β is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. 2014 , 1843, 1969-77	27

1701	Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer. 2014 , 2, 52-59	16
1700	Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. 2014 , 33, 966-76	41
1699	Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. 2014 , 32, 1695-702	22
1698	Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. 2014 , 16, R5	33
1697	Joint estimation of multiple related biological networks. 2014 , 8,	11
1696	Chronic disease prevention in primary care: how and when will genomics impact?. 2014 , 64, 331-2	5
1695	Imaging tumour heterogeneity of the consequences of a PKC β substrate interaction in breast cancer patients. 2014 , 42, 1498-505	10
1694	Expression of the adaptor protein Tks5 in human cancer: prognostic potential. 2014 , 32, 989-1002	17
1693	eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN. 2014 , 6, 1512-4	4
1692	Normal cell-type epigenetics and breast cancer classification: a case study of cell mixture-adjusted analysis of DNA methylation data from tumors. 2014 , 13, 53-64	12
1691	Modeling the altered expression levels of genes on signaling pathways in tumors as causal bayesian networks. 2014 , 13, 77-84	9
1690	ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer. 2014 , 32, 1071-7	22
1689	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. 2015 , 17, 80	5
1688	A new compact set of biomarkers for distinguishing among ten breast cancer subtypes. 2015 ,	0
1687	Global Analysis of mRNA, Translation, and Protein Localization: Local Translation Is a Key Regulator of Cell Protrusions. 2015 , 35, 344-57	74
1686	Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. 2015 , 4, 1016-30	24
1685	Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer. 2015 , 4, 1432-9	14
1684	IDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates. 2015 , 4, 415-25	4

1683	Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer. 2015 , 136, 2091-8	8
1682	Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. 2015 , 29, 2547-62	66
1681	Tumor Heterogeneity in Breast Cancer. 2015 , 22, 294-302	8
1680	Developmental genes significantly afflicted by aberrant promoter methylation and somatic mutation predict overall survival of late-stage colorectal cancer. 2015 , 5, 18616	10
1679	Information content and analysis methods for multi-modal high-throughput biomedical data. 2014 , 4, 4411	21
1678	An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. 2015 , 125, 959-66	18
1677	Overshoot during phenotypic switching of cancer cell populations. 2015 , 5, 15464	26
1676	Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. 2014 , 4, 6566	50
1675	EglN2 associates with the NRF1-PGC1 α complex and controls mitochondrial function in breast cancer. 2015 , 34, 2953-70	42
1674	Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. 2015 , 7, 299-314	22
1673	An introduction to systems genetics. 1-11	1
1672	Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma. 2015 , 5, 17787	108
1671	Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer. 2015 , 1, 15007	40
1670	Exploratory Methods to Integrate Multisource Data. 242-268	
1669	TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. 2015 , 5, 17879	7
1668	Targeting Breast Cancer Metastasis. 2015 , 9, 23-34	87
1667	Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?. 2015 , 31, 434-9	1
1666	Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. 2015 , 33, 526-32	9

1665	Context-Specific Effects of TGF- β /SMAD3 in Cancer Are Modulated by the Epigenome. 2015 , 13, 2480-2490	27
1664	Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein. 2015 , 15, 905	24
1663	Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. 2015 , 34, 1146-52	5
1662	A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. 2015 , 17, 4	20
1661	The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. 2015 , 7, 57	56
1660	Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients. 2015 , 36, 1088-99	6
1659	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. 2015 , 237, 166-78	42
1658	The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity. 2015 , 15, 630	9
1657	Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells. 2015 , 15, 896	8
1656	Common germline polymorphisms associated with breast cancer-specific survival. 2015 , 17, 58	24
1655	Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. 2015 , 17, 108	15
1654	An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. 2015 , 17, 131	50
1653	Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia. 2015 , 7, 28	15
1652	Gene expression meta-analysis reveals immune response convergence on the IFN γ /STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. 2015 , 7, 96	13
1651	The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. 2015 , 7, 126	17
1650	Dietary Carbohydrate, Glycemic Index, Glycemic Load, and Breast Cancer Risk Among Mexican Women. 2015 , 26, 917-24	14
1649	Categorization of cancer through genomic complexity could guide research and management strategies. 2015 , 236, 397-402	4
1648	Third Annual Open Meeting of the UK Pharmacogenomics and Stratified Medicine Network Conference. 2015 , 16, 775-8	1

1647	Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival. 2015 , 237, 152-65	55
1646	Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion. 2015 , 39, 1458-67	59
1645	Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer. 2015 , e183-90	15
1644	Genetic alterations in glioblastoma multiforme. 323-344	
1643	Prognostic and predictive value of PDL1 expression in breast cancer. 2015 , 6, 5449-64	313
1642	Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. 2015 , 14, 4282-90	11
1641	Targeted pathways in breast cancer: molecular and protein markers guiding therapeutic decisions. 2014 , 7, 4-21	21
1640	OECI-EACR precision medicine for cancer: Conference report 1-4 March 2015, Luxembourg. 2015 , 9, 519	
1639	Feature Selection for Nonlinear Regression and its Application to Cancer Research. 2015 ,	4
1638	Personalized Medicine in Cancer. 2015 , 32, 153-163	
1637	Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients. 2015 , 9,	15
1636	Matrix metalloproteinases as breast cancer drivers and therapeutic targets. 2015 , 20, 1144-63	83
1635	PP2A: The Wolf in Sheep's Clothing?. 2015 , 7, 648-69	46
1634	MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. 2015 , 16, 28347-76	46
1633	Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients. 2015 , 4, 1612-30	11
1632	Claudin 1 in Breast Cancer: New Insights. 2015 , 4, 1960-76	36
1631	Application of metabolomics in drug resistant breast cancer research. 2015 , 5, 100-18	38
1630	The GOLPH3 pathway regulates Golgi shape and function and is activated by DNA damage. 2015 , 9, 362	21

1629	High Expression of Three-Gene Signature Improves Prediction of Relapse-Free Survival in Estrogen Receptor-Positive and Node-Positive Breast Tumors. 2015 , 10, 103-12	19
1628	SimplePPT: A Simple Principal Tree Algorithm. 2015 ,	7
1627	p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. 2015 , 6, 43853-68	32
1626	Cytogenomics of Feline Cancers: Advances and Opportunities. 2015 , 2, 246-258	9
1625	A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases. 2015 , 10, e0115054	19
1624	Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer. 2015 , 10, e0120719	3
1623	HP1 β s a biomarker for breast cancer prognosis and PARP inhibitor therapy. 2015 , 10, e0121207	25
1622	Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets. 2015 , 11, e1004257	16
1621	The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set. 2015 , 10, e0129711	23
1620	DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells. 2015 , 10, e0131990	9
1619	Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration. 2015 , 10, e0133503	18
1618	Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer. 2015 , 10, e0144528	5
1617	Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis. 2015 , 61, 474-83	15
1616	Elevated ZNF703 Protein Expression Is an Independent Unfavorable Prognostic Factor for Survival of the Patients with Head and Neck Squamous Cell Carcinoma. 2015 , 2015, 640263	6
1615	Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition. 2015 , 6, 25320-38	26
1614	From mice to humans: developments in cancer immunoediting. 2015 , 125, 3338-46	188
1613	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. 2015 , 6, 37979-94	19
1612	Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival. 2015 , 6, 30500-15	48

1611	Breast cancer. 345-360	1
1610	Triple-negative breast cancer: molecular subtypes and new targets for therapy. 2015 , e31-9	83
1609	Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. 2015 , 107,	37
1608	Genomic profiling of breast cancers. 2015 , 27, 34-9	16
1607	Personalized Therapies for Cancer Treatment. 2015 , 317-346	
1606	Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR. 2015 , 17, 446-55	14
1605	BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. 2015 , 9, 1528-38	45
1604	HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive. 2015 , 8, ra52	16
1603	miR-30e* is an independent subtype-specific prognostic marker in breast cancer. 2015 , 113, 290-8	35
1602	Inference of transcriptional regulation in cancers. 2015 , 112, 7731-6	59
1601	Genome-wide analysis of alternative transcripts in human breast cancer. 2015 , 151, 295-307	16
1600	MicroRNA-30c-2-3p negatively regulates NF- κ B signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. 2015 , 9, 1106-19	61
1599	Pathway-based personalized analysis of breast cancer expression data. 2015 , 9, 1471-83	26
1598	Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer. 2015 , 15, 285	20
1597	Linking gene expression to phenotypes via pathway information. 2015 , 6, 17	20
1596	Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy. 2015 , 21, 4086-4096	10
1595	Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. 2015 , 21, 4165-73	58
1594	Tracing the footprints of the breast cancer oncogene BRK - Past till present. 2015 , 1856, 39-54	21

1593	Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series. 2015 , 6, 711-5	10
1592	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. 2015 , 26, 1488-93	179
1591	Computational and Statistical Epigenomics. 2015 ,	2
1590	Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. 2015 , 5, 97	29
1589	Probabilistic Graphical Models and Deep Belief Networks for Prognosis of Breast Cancer. 2015 ,	20
1588	A novel approach for finding informative genes in ten subtypes of breast cancer. 2015 ,	3
1587	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. 2015 , 1, 18-32	18
1586	Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer. 2015 , 106, 642-9	14
1585	Collateral Lethality: A new therapeutic strategy in oncology. 2015 , 1, 161-173	68
1584	Global transcription network incorporating distal regulator binding reveals selective cooperation of cancer drivers and risk genes. 2015 , 43, 5716-29	6
1583	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. 2015 , 99-127	4
1582	A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer. 2015 , 5, e006724	6
1581	MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. 2015 , 17, 83	36
1580	Prognostic and predictive immune gene signatures in breast cancer. 2015 , 27, 433-44	57
1579	DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. 2015 , 10, 1121-32	11
1578	Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. 2015 , 8, ra130	102
1577	Breast Cancer: Molecular Mechanisms, Diagnosis, and Treatment. 2015 , 155-200	1
1576	The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. 2015 , 6, 10077	33

1575	Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. 2015 , 177-195	1
1574	Molecular Pathology of Breast Cancer Metastasis. 2015 , 271-289	1
1573	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. 2015 , 17, 59	42
1572	The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation. 2015 , 11, 111-24	67
1571	Argininosuccinate lyase is a potential therapeutic target in breast cancer. 2015 , 34, 3131-9	23
1570	Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway. 2015 , 47, 231-43	28
1569	Transcriptomic analysis of human breast cancer cells reveals differentially expressed genes and related cellular functions and pathways in response to gold nanorods. 2015 , 1, 106-114	4
1568	Cancer Metastasis: Tracking and Attacking a Moving Target. 2015 , 1-13	
1567	A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer. 2015 , 21, 373-85	35
1566	Construction of a lncRNA-PCG bipartite network and identification of cancer-related lncRNAs: a case study in prostate cancer. 2015 , 11, 384-93	26
1565	Integrative analysis of cancer imaging readouts by networks. 2015 , 9, 1-16	14
1564	Spatially resolved metabolic phenotyping of breast cancer by desorption electrospray ionization mass spectrometry. 2015 , 75, 1828-37	105
1563	Regulation of polo-like kinase 1 by DNA damage and PP2A/B55. 2015 , 14, 157-66	24
1562	Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: a therapeutic target. 2015 , 150, 149-68	35
1561	A Big Bang model of human colorectal tumor growth. 2015 , 47, 209-16	646
1560	Patient-derived xenograft models of breast cancer and their predictive power. 2015 , 17, 17	195
1559	"Omics" in pharmaceutical research: overview, applications, challenges, and future perspectives. 2015 , 13, 3-21	43
1558	Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. 2015 , 27, 57-71	421

1557	CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. 2015 , 75, 1516-26	51
1556	Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. 2015 , 112, 912-7	11
1555	Computational and analytical challenges in single-cell transcriptomics. 2015 , 16, 133-45	736
1554	Inferring biological tasks using Pareto analysis of high-dimensional data. 2015 , 12, 233-5, 3 p following 235	93
1553	Decreased mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. 2015 , 2, 255-263	74
1552	NR2F1 controls tumour cell dormancy via SOX9- and RARE-driven quiescence programmes. 2015 , 6, 6170	163
1551	Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both Eatenin dependent and independent Wnt signalling. 2015 , 141, 243-54	48
1550	BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. 2015 , 6, 5987	94
1549	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. 2015 , 96, 5-20	59
1548	Intrinsic cancer subtypes--next steps into personalized medicine. 2015 , 38, 3-16	20
1547	Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. 2015 , 11, 251-81	78
1546	Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. 2015 , 14, 298-306	11
1545	The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. 2015 , 27, 193-210	235
1544	Cancer Systems Biology: The Future. 2015 , 297-314.e3	
1543	The Molecular Biology of Breast Cancer. 2015 , 523-530.e3	
1542	Understanding and Using Information about Cancer Genomes. 2015 , 357-368.e3	
1541	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. 2015 , 9, 115-27	35
1540	GLAD: a mixed-membership model for heterogeneous tumor subtype classification. 2015 , 31, 225-32	12

1539	Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. 2015 , 149, 425-37	25
1538	The landscape of long noncoding RNAs in the human transcriptome. 2015 , 47, 199-208	1789
1537	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. 2015 , 75, 245-9	120
1536	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. 2015 , 107,	72
1535	Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. 2015 , 14, 1057-65	32
1534	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. 2015 , 28, 766-77	79
1533	APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. 2015 , 112, 2841-6	95
1532	Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. 2015 , 17, 21	194
1531	Targeting the Tumor Stroma in Breast Cancer. 2015 , 7, 71-79	
1530	Adjuvant systemic therapy in breast cancer: quo vadis?. 2015 , 26, 1629-34	13
1529	Tumor hypoxia induces nuclear paraspeckle formation through HIF-2 α -dependent transcriptional activation of NEAT1 leading to cancer cell survival. 2015 , 34, 4482-90	164
1528	Targeting a cell state common to triple-negative breast cancers. 2015 , 11, 789	17
1527	The Cancer Genomics Resource List 2014. 2015 , 139, 989-1008	16
1526	Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. 2015 , 17, 15	22
1525	Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2. 2015 , 5, 506-19	27
1524	p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. 2015 , 112, 3499-504	115
1523	Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations. 2015 , 7, 6	6
1522	Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. 2015 , 34, 5427-35	57

1521	Moving ahead on harnessing synthetic lethality to fight cancer. 2015 , 2, e977150	
1520	A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. 2015 , 75, 3980-90	88
1519	The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. 2015 , 12, 992-1005	54
1518	Elevated TGF- β 1 and - β 2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. 2015 , 75, 151-8	33
1517	Over-expression of EPS15 is a favorable prognostic factor in breast cancer. 2015 , 11, 2978-85	6
1516	Gene-Expression-Based Predictors for Breast Cancer. 2015 , 22, 3418-32	19
1515	Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients. 2015 , 9, 1186-93	31
1514	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. 2015 , 21, 5082-5091	79
1513	Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers. 2015 , 29, 1631-48	69
1512	Unsaturated fatty acids as high-affinity ligands of the C-terminal Per-ARNT-Sim domain from the Hypoxia-inducible factor 3 β . 2015 , 5, 12698	12
1511	Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia. 2015 , 5, 16	18
1510	[Molecular taxonomy of luminal breast cancer in 2015]. 2015 , 102, S34-46	5
1509	TIPIN depletion leads to apoptosis in breast cancer cells. 2015 , 9, 1580-98	14
1508	Progesterone receptor modulates ER α action in breast cancer. <i>Nature</i> , 2015 , 523, 313-7	50.4 376
1507	Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. 2015 , 230, 1708-12	5
1506	Improving Outcomes for Breast Cancer Survivors. 2015 ,	7
1505	Targeting increased copper levels in diethylnitrosamine induced hepatocellular carcinoma cells in rats by epigallocatechin-3-gallate. 2015 , 36, 8861-7	15
1504	Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. 2015 , 11, 1549-63	48

1503	Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. 2015 , 22, 33-48	81
1502	CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. 2015 , 152, 337-46	19
1501	Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. 2015 , 5, 12133	30
1500	Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. 2015 , 75, 2963-8	218
1499	Systems Epigenomics and Applications to Ageing and Cancer. 2015 , 161-185	
1498	Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. 2015 , 12, 511-24	28
1497	Intra-tumour signalling entropy determines clinical outcome in breast and lung cancer. 2015 , 11, e1004115	33
1496	TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. 2015 , 152, 519-31	24
1495	Host Factors and Risk of Breast Cancer Recurrence: Genetic, Epigenetic and Biologic Factors and Breast Cancer Outcomes. 2015 , 862, 143-53	10
1494	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. 2015 , 97, 22-34	26
1493	Network-based approaches for drug response prediction and targeted therapy development in cancer. 2015 , 464, 386-91	23
1492	Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. 2015 , 68, 362-7	15
1491	Genetically Determined Variation in Developmental Physiology of Bivalve Larvae (<i>Crassostrea gigas</i>). 2015 , 88, 128-36	9
1490	NCC-AUC: an AUC optimization method to identify multi-biomarker panel for cancer prognosis from genomic and clinical data. 2015 , 31, 3330-8	14
1489	Personalized radiotherapy: concepts, biomarkers and trial design. 2015 , 88, 20150009	20
1488	Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. 2015 , 22, S29-42	14
1487	A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers. 2015 , 139, 612-7	28
1486	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. 2015 , 17, 35	7

1485	Immune biomarkers: how well do they serve prognosis in human cancers?. 2015 , 15, 49-59	5
1484	Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. 2015 , 9, 877-88	14
1483	Identification of novel genetic markers of breast cancer survival. 2015 , 107,	38
1482	Loss of GM130 in breast cancer cells and its effects on cell migration, invasion and polarity. 2015 , 14, 1139-47	13
1481	The proteomic landscape of triple-negative breast cancer. 2015 , 11, 630-44	130
1480	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. 2015 , 9, 569-85	57
1479	Molecular Signatures of Local Control in Breast Cancer. 2015 , 26, 16-18	
1478	Cell signaling events differentiate ER-negative subtypes from ER-positive breast cancer. 2015 , 32, 142	4
1477	Clinical management of breast cancer heterogeneity. 2015 , 12, 381-94	285
1476	Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. 2015 , 36, 1835-48	19
1475	Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. 2015 , 17, 12	170
1474	Molecular subtyping for clinically defined breast cancer subgroups. 2015 , 17, 29	40
1473	Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. 2015 , 17, 25	137
1472	Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. 2015 , 17, 31	26
1471	Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer. 2015 , 16, 61	5
1470	Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells. 2015 , 5, 10	9
1469	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. 2015 , 5, 488-505	76
1468	p84 forms a negative regulatory complex with p110 α to control PI3K signalling during cell migration. 2015 , 93, 735-43	7

1467	Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. 2015 , 33, 2035-40	79
1466	Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. 2015 , 8, ra7	40
1465	Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. 2015 , 15, 179	11
1464	FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis. 2015 , 24, 3506-17	18
1463	Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. 2015 , 8, 237-51	100
1462	Protein Kinase CK2 Cellular Function in Normal and Disease States. 2015 ,	3
1461	Clinical proteomics and breast cancer. 2015 , 13, 271-8	23
1460	Glycan-related gene expression signatures in breast cancer subtypes; relation to survival. 2015 , 9, 861-76	36
1459	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. 2015 , 26, 1791-8	58
1458	Cyclin E deregulation promotes loss of specific genomic regions. 2015 , 25, 1327-33	47
1457	Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?. 2015 , 41, 547-53	31
1456	Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. 2015 , 12,	50
1455	Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. 2015 , 9, 1274-86	20
1454	Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients. 2015 , 150, 457-466	6
1453	Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. 2015 , 25, 714-24	88
1452	An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. 2015 , 21, 3252-62	23
1451	Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. 2015 , 107, djv077	69
1450	Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation. 2015 , 151, 121-40	29

1449	New approaches for improving outcomes in breast cancer in Europe. 2015 , 24, 321-30	37
1448	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. 2015 , 112, 5425-30	132
1447	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. 2015 , 75, 41-50	54
1446	MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. 2015 , 93, 1104-14	16
1445	4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. 2015 , 153, 647-58	37
1444	Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. 2015 , 6, 8323	59
1443	The changing role of ER in endocrine resistance. 2015 , 24 Suppl 2, S60-6	62
1442	FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. 2015 , 27, 2496-505	76
1441	Heat Shock Proteins in Triple-Negative Breast Cancer (TNBC) Treatment. 2015 , 129-149	1
1440	Genomic landscapes of breast fibroepithelial tumors. 2015 , 47, 1341-5	129
1439	Race-associated biological differences among Luminal A breast tumors. 2015 , 152, 437-48	42
1438	Classification via correlation-based feature grouping. 2015 ,	
1437	Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data. 2015 , 2, 041007	99
1436	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. 2015 , 36, 822-846	191
1435	Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. 2015 , 13, 493-501	48
1434	Clinical and molecular complexity of breast cancer metastases. 2015 , 35, 85-95	86
1433	Targeting Ribonucleotide Reductase M2 and NF- κ B Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer. 2015 , 14, 2411-21	40
1432	DECODE: an integrated differential co-expression and differential expression analysis of gene expression data. 2015 , 16, 182	23

1431	The path to routine use of genomic biomarkers in the cancer clinic. 2015 , 25, 1508-13	26
1430	A Gene Regulatory Program in Human Breast Cancer. 2015 , 201, 1341-8	8
1429	Targeted therapies for ER+/HER2- metastatic breast cancer. 2015 , 13, 137	51
1428	Precision Molecular Pathology of Breast Cancer. 2015 ,	3
1427	Heat Shock Protein-Based Therapies. 2015 ,	4
1426	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. 2015 , 152, 347-56	37
1425	Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. <i>Nature</i> , 2015 , 525, 119-23	50.4 213
1424	Classical pathology and mutational load of breast cancer - integration of two worlds. 2015 , 1, 225-38	57
1423	Biobanking in the 21st Century. 2015 ,	4
1422	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. 2015 , 13, 277-89	137
1421	Mammakarzinom Update 2014 Die Patientin und der Tumor im Mittelpunkt. 2015 , 12, 31-43	
1420	Breast Cancer Update 2014 - Focus on the Patient and the Tumour. 2015 , 75, 170-182	8
1419	Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas. 2015 , 15, 524	12
1418	Differential DNA methylation and expression of inflammatory and zinc transporter genes defines subgroups of osteoarthritic hip patients. 2015 , 74, 1778-82	19
1417	Mammakarzinom Update 2014 Die Patientin und der Tumor im Mittelpunkt. 2015 , 36, 213-225	
1416	The MEF2-HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro. 2015 , 128, 3961-76	17
1415	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. 2015 , 13, 108-121	64
1414	Biomarker für Patientinnen mit metastasiertem Mammakarzinom und das PRAEGNANT-Studiennetzwerk. 2015 , 12, 85-94	

1413	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. 2015 , 163, 506-19	1055
1412	Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. 2015 , 4, e168	24
1411	Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. 2015 , 6, 8554	71
1410	Dimensionality Reduction Via Graph Structure Learning. 2015 ,	39
1409	A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. 2015 , 212, 1551-69	27
1408	Molecular Classification of Breast Cancer. 2015 , 137-155	
1407	Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures. 2015 , 16, 1000-7	6
1406	Lipid phosphate phosphatases and their roles in mammalian physiology and pathology. 2015 , 56, 2048-60	87
1405	Modelling the Molecular Pathology of Breast Cancer Initiation. 2015 , 39-50	1
1404	Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer. 2015 , 26, 489-98	66
1403	Proangiogenic Properties of Thrombospondin-4. 2015 , 35, 1975-86	44
1402	Clinical implications of the intrinsic molecular subtypes of breast cancer. 2015 , 24 Suppl 2, S26-35	450
1401	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. 2015 , 16, 107	83
1400	Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. 2015 , 2, 1133-44	143
1399	A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. 2015 , 75, 4651-64	143
1398	Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival. 2015 , 112, 12217-22	36
1397	An integrated network platform for contextual prioritization of drugs and pathways. 2015 , 11, 2850-9	6
1396	Copy number analysis of ductal carcinoma in situ with and without recurrence. 2015 , 28, 1174-84	28

1395	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. 2015 , 107, djv256	60
1394	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. 2015 , 24, 1680-91	17
1393	Reconstructing and analysing cellular states, space and time from gene expression profiles of many cells and single cells. 2015 , 11, 2690-8	2
1392	Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. <i>Nature</i> , 2015 , 528, 267-71	50.4 75
1391	A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. 2015 , 24 Suppl 2, S23-5	2
1390	Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. 2015 , 11, 564-76	41
1389	Molecular subtyping of prostate cancer: a partnership model. 2015 , 68, 568-9	1
1388	The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical-genomic driver associations. 2015 , 7, 112	58
1387	Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. 2015 , 60, 537-46	163
1386	Genetics: Big hopes for big data. <i>Nature</i> , 2015 , 527, S108-9	50.4 31
1385	FOXC1 Activates Smoothed-Independent Hedgehog Signaling in Basal-like Breast Cancer. 2015 , 13, 1046-58	94
1384	Primary Systemic Treatment in the Management of Operable Breast Cancer: Best Surgical Approach for Diagnosis, Biological Evaluation, and Research. 2015 , 2015, 4-8	7
1383	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. 2015 , 9, 2054-62	60
1382	Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7. 2015 , 33, 429-39	15
1381	An Arf-Egr-C/EBP β pathway linked to ras-induced senescence and cancer. 2015 , 35, 866-83	27
1380	Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. 2015 , 147, 63-79	23
1379	Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer. 2014 , 4, 7063	31
1378	Hypoxic regulation of R1OK3 is a major mechanism for cancer cell invasion and metastasis. 2015 , 34, 4713-22	32

1377	Absolute assignment of breast cancer intrinsic molecular subtype. 2015 , 107, 357	79
1376	Pathway-level disease data mining through hyper-box principles. 2015 , 260, 25-34	5
1375	CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population. 2015 , 34, 4656-63	9
1374	MicroRNA signatures highlight new breast cancer subtypes. 2015 , 556, 192-8	29
1373	Inhibitors of p21-activated kinases (PAKs). 2015 , 58, 111-29	80
1372	Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].. 2015 , 28, 340-51	56
1371	Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer. 2015 , 9, 58-67	25
1370	Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. 2015 , 111, 81-90	23
1369	A reason for intermittent fasting to suppress the awakening of dormant breast tumors. 2015 , 127, 1-6	4
1368	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. 2015 , 34, 3968-76	56
1367	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. <i>Nature</i> , 2015 , 518, 422-6	50.4 451
1366	Is reduction of tumor burden sufficient for the 21st century?. 2015 , 356, 149-55	1
1365	Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. 2015 , 21, 1688-98	659
1364	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. 2015 , 30, 689-721	79
1363	ER α decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. 2015 , 34, 4130-41	38
1362	A DNA methylation-based definition of biologically distinct breast cancer subtypes. 2015 , 9, 555-68	117
1361	NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. 2015 , 34, 3780-90	35
1360	Intratumoural inflammation and endocrine resistance in breast cancer. 2015 , 22, R51-67	17

1359	Translating the molecular message of triple-negative breast cancer into targeted therapy. 2015 , 21, 1511-3	6
1358	Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. 2015 , 9, 204-17	55
1357	Cancer evolution: mathematical models and computational inference. 2015 , 64, e1-25	181
1356	Variational Bayesian Matrix Factorization for Bounded Support Data. 2015 , 37, 876-89	118
1355	Breast tumor subgroups reveal diverse clinical prognostic power. 2014 , 4, 4002	47
1354	Breast cancer classification: linking molecular mechanisms to disease prognosis. 2015 , 16, 461-74	40
1353	RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch. 2015 , 34, 2189-203	26
1352	PKA signaling drives mammary tumorigenesis through Src. 2015 , 34, 1160-73	60
1351	Nanoparticulate carriers: an emerging tool for breast cancer therapy. 2015 , 23, 97-108	10
1350	Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status. 2015 , 36, 711-8	0
1349	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. 2015 , 34, 3617-26	165
1348	Genomic Applications in Pathology. 2015 ,	
1347	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. 2016 , 7, 32731-53	25
1346	Cancer Biomarkers. 2016 ,	3
1345	New generation of breast cancer clinical trials implementing molecular profiling. 2016 , 13, 226-35	3
1344	Metabolic Effect of Estrogen Receptor Agonists on Breast Cancer Cells in the Presence or Absence of Carbonic Anhydrase Inhibitors. 2016 , 6,	6
1343	Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis. 2016 , 467-477	
1342	Epigenetic Alterations in Endocrine-Dependent Cancers: Implications of Endocrine Dysfunctions. 2016 , 351-374	

1341	ART3 regulates triple-negative breast cancer cell function via activation of Akt and ERK pathways. 2016 , 7, 46589-46602	13
1340	Proximal and distal regulation of the HYAL1 gene cluster by the estrogen receptor in breast cancer cells. 2016 , 7, 77276-77290	11
1339	A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms. 2016 , 16, 793-801	27
1338	Life as an early career researcher: interview with Heloisa Helena Milioli. 2016 , 2, FSO128	
1337	Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. 2016 , 7, 52493-52516	11
1336	Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?. 2016 , 35, e31-8	5
1335	Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. 2016 , 7, 62939-62953	19
1334	Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. 2016 , 7, 26724-38	12
1333	The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. 2016 , 7, 73-85	13
1332	The Occurrence of Genetic Alterations during the Progression of Breast Carcinoma. 2016 , 2016, 5237827	5
1331	A Novel Graph-based Algorithm to Infer Recurrent Copy Number Variations in Cancer. 2016 , 15, 43-50	1
1330	Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients. 2016 , 2016, 3239167	3
1329	Insights into a Critical Role of the FOXO3a-FOXO1 Axis in DNA Damage Response and Genotoxic Drug Resistance. 2016 , 17, 164-77	43
1328	Global, quantitative and dynamic mapping of protein subcellular localization. 2016 , 5,	282
1327	The Genome Conformation As an Integrator of Multi-Omic Data: The Example of Damage Spreading in Cancer. 2016 , 7, 194	15
1326	A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis. 2016 , 17,	29
1325	Mobilization of Intracellular Copper by Gossypol and Apogossypolone Leads to Reactive Oxygen Species-Mediated Cell Death: Putative Anticancer Mechanism. 2016 , 17,	13
1324	Cancer Cell Fusion: Mechanisms Slowly Unravel. 2016 , 17,	33

1323	Discovering causal interactions using Bayesian network scoring and information gain. 2016 , 17, 221	26
1322	Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients. 2016 , 16, 821	17
1321	A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer. 2016 , 9, 287	1
1320	Lentivirus-mediated knockdown of CEP55 suppresses cell proliferation of breast cancer cells. 2016 , 10, 67-73	35
1319	Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. 2016 , 13, e1001961	74
1318	Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. 2016 , 13, e1002194	282
1317	Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines. 2016 , 11, e0145647	14
1316	Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging. 2016 , 11, e0158404	26
1315	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. 2016 , 11, e0167397	4
1314	The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. 2016 , 17, 566	61
1313	Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. 2016 , 7, 40418-40436	112
1312	A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. 2016 , 9, 1389-98	38
1311	Chromosomal breakpoints in breast cancer co-localize with differentially methylated regions. 255-268	
1310	Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. 2016 , 49, 409-20	22
1309	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. 2016 , 158, 441-54	18
1308	Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. 2016 , 16, 1166-1179	56
1307	Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. 2016 , 18, 70	9
1306	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. 2016 , 238, 508-18	80

1305	Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels. 2016 , 16, 672-83	19
1304	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. 2016 , 238, 677-88	42
1303	Subtype-specific micro-RNA expression signatures in breast cancer progression. 2016 , 139, 1117-28	42
1302	Covariate dimension reduction for survival data via the Gaussian process latent variable model. 2016 , 35, 1340-53	0
1301	Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples. 2016 , 18, 69	8
1300	PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. 2016 , 18, 95	19
1299	Prognostic factor analysis for breast cancer using gene expression profiles. 2016 , 16 Suppl 1, 56	7
1298	ZNF703 Overexpression may act as an oncogene in non-small cell lung cancer. 2016 , 5, 2873-2878	17
1297	Long intergenic non-coding RNA expression signature in human breast cancer. 2016 , 6, 37821	20
1296	Big Data Bioinformatics. 2016 , 111, 1-2	8
1295	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. 2016 , 17, 140	46
1294	High-dimensional genomic data bias correction and data integration using MANCIE. 2016 , 7, 11305	28
1293	Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. 2016 , 9, 749-57	14
1292	AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. 2016 , 16, 622	50
1291	Stratification and therapeutic potential of PML in metastatic breast cancer. 2016 , 7, 12595	26
1290	Modeling Breast Cancer Intertumor and Intratumor Heterogeneity Using Xenografts. 2016 , 81, 227-230	7
1289	Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. 2016 , 6, 27391	19
1288	Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. 2016 , 18, 74	41

1287	Recent developments and translational aspects in targeted therapy for metastatic breast cancer. 2016 , 1, e000036	1
1286	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. 2016 , 6, 18517	96
1285	LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. 2016 , 8, 1052-64	66
1284	Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics. 2016 , 6, 24949	14
1283	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. 2016 , 18, 64	25
1282	p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis. 2016 , 7, 13874	11
1281	Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis. 2016 , 2, 16037	3
1280	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. 2016 , 35, 547-573	133
1279	FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3. 2016 , 17, 2715-2723	78
1278	Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. 2016 , 2, e1501924	69
1277	'Omics Approaches in Breast Cancer Research and Clinical Practice. 2016 , 23, 356-367	15
1276	Elevated STC-1 augments the invasiveness of triple-negative breast cancer cells through activation of the JNK/c-Jun signaling pathway. 2016 , 36, 1764-71	23
1275	Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production. 2016 , 6, 19771	24
1274	A review of biomechanically informed breast image registration. 2016 , 61, R1-31	37
1273	Targeting Androgen/Estrogen Receptors Crosstalk in Cancer. 2016 , 2, 35-48	29
1272	A quest towards personalised medicine for grade II meningiomas--will need to zoom in. 2016 , 158, 931-2	1
1271	Proteogenomics connects somatic mutations to signalling in breast cancer. <i>Nature</i> , 2016 , 534, 55-62	50.4 938
1270	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. 2016 , 76, 4236-48	25

1269	Does Biology Transcend the Symptom-based Boundaries of Psychosis?. 2016 , 39, 165-74	24
1268	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. 2016 , 18, 632-44	124
1267	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. 2016 , 13, 674-690	1246
1266	Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. 2016 , 114, 1395-404	57
1265	Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. 2016 , 76, 3166-78	32
1264	Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins. 2016 , 76, 4068-80	50
1263	Noninvasive strategies for breast cancer early detection. 2016 , 12, 1395-411	10
1262	Forkhead box A1 (FOXA1) tagging polymorphisms and esophageal cancer risk in a Chinese population: a fine-mapping study. 2016 , 21, 523-9	3
1261	SNRFCB: sub-network based random forest classifier for predicting chemotherapy benefit on survival for cancer treatment. 2016 , 12, 1214-23	5
1260	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. 2016 , 76, 1942-53	51
1259	Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer. 2016 , 34, 1838-9	2
1258	All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. 2016 , 283, 1004-24	175
1257	c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/ECatenin/Axin2 Pathway. 2016 , 76, 3364-75	72
1256	Signatures of breast cancer metastasis at a glance. 2016 , 129, 1751-8	38
1255	Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression. 2016 , 35, 5170-8	36
1254	GenomeRunner web server: regulatory similarity and differences define the functional impact of SNP sets. 2016 , 32, 2256-63	25
1253	Claudin 1 Expression Levels Affect miRNA Dynamics in Human Basal-Like Breast Cancer Cells. 2016 , 35, 328-39	10
1252	The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. 2016 , 16, 751-5	15

1251	Ly6E/K Signaling to TGF β Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance. 2016 , 76, 3376-86	51
1250	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016 , 534, 47-54	1193
1249	Breast Cancer: A Molecular and Redox Snapshot. 2016 , 25, 337-70	10
1248	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. 2016 , 28, 373-82	108
1247	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. 2016 , 22, 5238-5248	30
1246	Major milestones in translational oncology. 2016 , 14, 110	9
1245	Prolactin-Inducible Protein: From Breast Cancer Biomarker to Immune Modulator—Novel Insights from Knockout Mice. 2016 , 35, 537-541	15
1244	Simultaneous discovery of cancer subtypes and subtype features by molecular data integration. 2016 , 32, i445-i454	21
1243	Pushing estrogen receptor around in breast cancer. 2016 , 23, T227-T241	26
1242	Comparing continuous and discrete analyses of breast cancer survival information. 2016 , 108, 78-83	3
1241	Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?. 2016 , 10, 1497-1515	45
1240	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. 2016 , 76, 6495-6506	68
1239	The genomic landscape of breast cancer and its interaction with host immunity. 2016 , 29, 241-50	130
1238	Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. 2016 , 23, 635-50	5
1237	Patient-derived tumour xenografts for breast cancer drug discovery. 2016 , 23, T259-T270	10
1236	Information theoretic sub-network mining characterizes breast cancer subtypes in terms of cancer core mechanisms. 2016 , 14, 1644002	0
1235	Elementary: breast cancer culprits leave their signatures on the double helix. 2016 , 23, 1577-8	
1234	Renewed interest in the progesterone receptor in breast cancer. 2016 , 115, 909-911	20

1233	Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma. 2016 , 37, 13855-13870	16
1232	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. 2016 , 29, 1292-1305	52
1231	Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. 2016 , 16, 2032-46	30
1230	Spatial Heterogeneity in the Tumor Microenvironment. 2016 , 6,	116
1229	MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4. 2016 , 16, 225-233	69
1228	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. 2016 , 21, 1063-78	35
1227	Somatic TP53 Mutations in the Era of Genome Sequencing. 2016 , 6,	115
1226	Hereditary breast and ovarian cancer: new genes in confined pathways. 2016 , 16, 599-612	210
1225	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17. 2016 , 76, 5881-5893	37
1224	Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. 2016 , 138, 87-97	79
1223	Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. 2016 , 139, 12-22	30
1222	An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer. 2016 , 115, 752-60	10
1221	Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes. 2016 , 107, 828-35	21
1220	RANKL Signaling and ErbB Receptors in Breast Carcinogenesis. 2016 , 22, 839-850	13
1219	Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. 2016 , 48, 1260-6	53
1218	Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. 2016 , 17 Suppl 7, 525	97
1217	Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?. 2016 , 8,	41
1216	Challenging Roadblocks to Cancer Cure. 2016 , 76, 4924-30	3

1215	Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. 2016 , 240, 315-328	24
1214	11a-N-Tosyl-5-deoxy-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes. 2016 , 142, 2119-30	3
1213	RUNX1 contributes to higher-order chromatin organization and gene regulation in breast cancer cells. 2016 , 1859, 1389-1397	43
1212	Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. 2016 , 113, 9810-5	45
1211	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. 2016 , 159, 215-27	59
1210	ERXPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization. 2016 , 30, 1029-1045	13
1209	Frontiers in Cancer Research. 2016 ,	
1208	Trastuzumab-associated cardiac events in the Persephone trial. 2016 , 115, 1462-1470	20
1207	Systems Approaches to Cancer Biology. 2016 , 76, 6774-6777	14
1206	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. 2016 , 2, 16022	18
1205	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. 2016 , 2, 16036	89
1204	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. 2016 , 167, 260-274.e22	274
1203	Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications. 2016 , 37, 14479-14499	5
1202	Invasive Lobular Carcinoma. 2016 , 595-620	
1201	MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. 2016 , 16, 695	4
1200	Genomic profiling of breast cancer in African-American women using MammaPrint. 2016 , 159, 481-8	7
1199	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. 2016 , 111, 577-591	26
1198	A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. 2016 , 63, 514-25	99

1197	An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. 2016 , 59, 9575-9598	111
1196	Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors. 2016 , 15, 2256-62	15
1195	Examining Functional Resting-State Connectivity in Psychosis and Its Subgroups in the Bipolar-Schizophrenia Network on Intermediate Phenotypes Cohort. 2016 , 1, 488-497	17
1194	Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. 2016 , 113, E7749-E7758	43
1193	One microenvironment does not fit all: heterogeneity beyond cancer cells. 2016 , 35, 601-629	41
1192	The influence of personality and perceived stress on the development of breast cancer: 20-year follow-up of 29,098 Japanese women. 2016 , 6, 32559	13
1191	Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer. 2016 , 8, 114	2
1190	A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. 2016 , 7, 12222	77
1189	Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer. 2016 , 6, 33899	27
1188	FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. 2016 , 37, 741-750	28
1187	Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer. 2016 , 6, 21374	13
1186	Breast cancer subtype predictors revisited: from consensus to concordance?. 2016 , 9, 26	4
1185	Progress in the clinical detection of heterogeneity in breast cancer. 2016 , 5, 3475-3488	39
1184	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. 2016 , 22, 1303-1313	127
1183	Ion channels expression and function are strongly modified in solid tumors and vascular malformations. 2016 , 14, 285	31
1182	Investigation of breast cancer sub-populations in black and white women in South Africa. 2016 , 160, 531-537	10
1181	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. 2016 , 7, 12675	53
1180	Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer. 2016 , 6, 34000	5

1179	Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations. 2016 , 76, 6785-6794	3
1178	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). 2016 , 6, 32512	16
1177	Rawcopy: Improved copy number analysis with Affymetrix arrays. 2016 , 6, 36158	43
1176	A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer. 2016 , 6, 29662	30
1175	HLA-C Level Is Regulated by a Polymorphic Oct1 Binding Site in the HLA-C Promoter Region. 2016 , 99, 1353-1358	35
1174	Classification of breast cancer patients using somatic mutation profiles and machine learning approaches. 2016 , 10 Suppl 3, 62	34
1173	Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. 2016 , 6, 36231	17
1172	Wars2 is a determinant of angiogenesis. 2016 , 7, 12061	31
1171	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. 2016 , 7, 12791	152
1170	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. 2016 , 7, 12910	74
1169	Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. 2016 , 6, 19435	69
1168	The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. 2016 , 7, 11479	779
1167	Comprehensive functional analysis of the tousel-like kinase 2 frequently amplified in aggressive luminal breast cancers. 2016 , 7, 12991	29
1166	"Big Data" for Breast Cancer: Where to look and what you will find. 2016 , 2,	12
1165	MUFINS: multi-formalism interaction network simulator. 2016 , 2, 16032	14
1164	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. 2016 , 8, 1-14	25
1163	A systematic comparison of copy number alterations in four types of female cancer. 2016 , 16, 913	7
1162	Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. 2016 , 18, 56	30

1161	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. 2016 , 18, 92	32
1160	CrossLink: a novel method for cross-condition classification of cancer subtypes. 2016 , 17 Suppl 7, 549	0
1159	RECQL4 helicase has oncogenic potential in sporadic breast cancers. 2016 , 238, 495-501	29
1158	YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. 2016 , 17, 188-201	116
1157	Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. 2016 , 16, 204	29
1156	Comprehensive Gene Mutation Profiling of Breast Tumors: Is It Ready for Prime Time Use?. 2016 , 8, 53-59	
1155	Network-based analysis for identification of candidate genes for colorectal cancer progression. 2016 , 476, 534-540	10
1154	The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. 2016 , 14, 20	48
1153	ICM: a web server for integrated clustering of multi-dimensional biomedical data. 2016 , 44, W154-9	13
1152	Tetracyclines increase lipid phosphate phosphatase expression on plasma membranes and turnover of plasma lysophosphatidate. 2016 , 57, 597-606	22
1151	Predicting chemoinsensitivity in breast cancer with 'omics/digital pathology data fusion. 2016 , 3, 140501	10
1150	RNA Sequencing and Genetic Disease. 2016 , 4, 49-56	
1149	Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management. 2016 , 28, 136-44	67
1148	Zinc finger factor ZNF121 is a MYC-interacting protein functionally affecting MYC and cell proliferation in epithelial cells. 2016 , 43, 677-685	10
1147	Protein interaction network (PIN)-based breast cancer subsystem identification and activation measurement for prognostic modeling. 2016 , 110, 81-89	12
1146	miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer. 2016 , 76, 5151-62	56
1145	Statistical Methods in Integrative Genomics. 2016 , 3, 181-209	52
1144	The voltage gated Ca(2+)-channel Cav3.2 and therapeutic responses in breast cancer. 2016 , 16, 24	24

1143	Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset. 2016 , 9, 2	13
1142	Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. 2016 , 18, 9	16
1141	An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. 2016 , 18, 27	51
1140	The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. 2016 , 8, 38	40
1139	HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. 2016 , 76, 4443-56	41
1138	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer. 2016 , 22, 5929-5938	47
1137	Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. 2016 , 56, 40-51	7
1136	SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. 2016 , 17, 1004-1018	65
1135	Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry. 2016 , 17, 635-47	17
1134	Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. 2016 , 15, 2705-18	58
1133	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. 2016 , 18, 21	43
1132	Block-Constraint Robust Principal Component Analysis and its Application to Integrated Analysis of TCGA Data. 2016 , 15, 510-516	16
1131	HIF1- β activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. 2016 , 113, E3735-44	37
1130	Uterine adenosarcomas are mesenchymal neoplasms. 2016 , 238, 381-8	70
1129	Integrative methods for analyzing big data in precision medicine. 2016 , 16, 741-58	120
1128	Algorithmic methods to infer the evolutionary trajectories in cancer progression. 2016 , 113, E4025-34	49
1127	Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci. 2016 , 25, 3361-3371	22
1126	Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. 2016 , 8, 159-180	27

1125	Molecular mechanisms associated with breast cancer based on integrated gene expression profiling by bioinformatics analysis. 2016 , 36, 615-21	8
1124	Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. 2016 , 7, 10358	62
1123	Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach. 2016 , 12, 963-72	21
1122	Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies. 2016 , 10, 494-502	54
1121	A headlight on liquid biopsies: a challenging tool for breast cancer management. 2016 , 37, 4263-73	17
1120	Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. 2016 , 10, 464-74	82
1119	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. 2016 , 164, 293-309	259
1118	Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy. 2016 , 22, 2271-82	39
1117	Double-stranded microRNA mimics can induce length- and passenger strand-dependent effects in a cell type-specific manner. 2016 , 22, 193-203	28
1116	Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. 2016 , 16, 39-50	9
1115	Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers. 2016 , 173, 373-84	396
1114	Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers. 2016 , 132, 112-30	25
1113	Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer. 2016 , 10, 179-93	18
1112	Sparse Variational Bayesian approximations for nonlinear inverse problems: Applications in nonlinear elastography. 2016 , 299, 215-244	16
1111	Intratumor Heterogeneity in Breast Cancer. 2016 , 882, 169-89	81
1110	p53MutaGene: an online tool to estimate the effect of p53 mutational status on gene regulation in cancer. 2016 , 7, e2148	8
1109	Integrative clustering methods of multi-omics data for molecule-based cancer classifications. 2016 , 4, 58-67	37
1108	Novel Biomarkers in the Continuum of Breast Cancer. 2016 ,	9

1107	Nuclear tristetraprolin acts as a corepressor of multiple steroid nuclear receptors in breast cancer cells. 2016 , 7, 20-6	12
1106	Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes. 2016 , 65, 1434-46	9
1105	Breast pathology. 2016 , 34, 1-7	
1104	Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. 2016 , 23, 1152-64	24
1103	GOS2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. 2016 , 76, 1204-13	26
1102	GSE1 negative regulation by miR-489-5p promotes breast cancer cell proliferation and invasion. 2016 , 471, 123-8	33
1101	The Genomic Landscape of Male Breast Cancers. 2016 , 22, 4045-56	85
1100	Leukaemia 'firsts' in cancer research and treatment. 2016 , 16, 163-72	46
1099	Whole exome sequencing of rare aggressive breast cancer histologies. 2016 , 156, 21-32	26
1098	The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. 2016 , 156, 9-20	22
1097	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. 2016 , 48, 374-86	93
1096	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. 2016 , 34, 2341-9	185
1095	SynTarget: an online tool to test the synergetic effect of genes on survival outcome in cancer. 2016 , 23, 912	37
1094	Immunohistochemistry for Triple-Negative Breast Cancer. 2016 , 1406, 39-51	2
1093	Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. 2016 , 35, 4495-508	14
1092	Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. 2016 , 27, 1041-1047	32
1091	Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors. 2016 , 99, 1009-25	21
1090	High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer. 2016 , 382, 77-85	24

1089	System-wide Clinical Proteomics of Breast Cancer Reveals Global Remodeling of Tissue Homeostasis. 2016 , 2, 172-84	63
1088	MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. 2016 , 114, 917-28	64
1087	Catalog of genetic progression of human cancers: breast cancer. 2016 , 35, 49-62	14
1086	Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy, and Recurrence in Breast Cancer. 2016 , 22, 3651-62	5
1085	The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks. 2016 , 1859, 792-804	46
1084	Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. 2016 , 37, 188-196	30
1083	Predictors of tumor-infiltrating lymphocyte efficacy in melanoma. 2016 , 8, 35-43	17
1082	Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. 2016 , 7, 10248	30
1081	moCluster: Identifying Joint Patterns Across Multiple Omics Data Sets. 2016 , 15, 755-65	48
1080	Proteomic maps of breast cancer subtypes. 2016 , 7, 10259	178
1079	HER2 drives Mucin-like 1 to control proliferation in breast cancer cells. 2016 , 35, 4225-34	19
1078	An integrated genomic analysis of Tudor domain-containing proteins identifies PHD finger protein 20-like 1 (PHF20L1) as a candidate oncogene in breast cancer. 2016 , 10, 292-302	19
1077	Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. 2016 , 37, 63-71	25
1076	Regulators of genetic risk of breast cancer identified by integrative network analysis. 2016 , 48, 12-21	100
1075	Computational pathology: Exploring the spatial dimension of tumor ecology. 2016 , 380, 296-303	31
1074	Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. 2016 , 32, 1097-9	150
1073	Vegetable and fruit consumption and the risk of hormone receptor-defined breast cancer in the EPIC cohort. 2016 , 103, 168-77	40
1072	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. 2016 , 35, 1877-87	83

1071	Meta-analytic framework for sparse -means to identify disease subtypes in multiple transcriptomic studies. 2016 , 111, 27-42	15
1070	Neddylation controls basal MKK7 kinase activity in breast cancer cells. 2016 , 35, 2624-33	13
1069	Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. 2016 , 22, 146-57	29
1068	ZNF281 contributes to the DNA damage response by controlling the expression of XRCC2 and XRCC4. 2016 , 35, 2592-601	25
1067	Public data and open source tools for multi-assay genomic investigation of disease. 2016 , 17, 603-15	38
1066	Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. 2016 , 5, e1061176	19
1065	Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. 2016 , 35, 1743-9	11
1064	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. 2016 , 35, 1517-28	41
1063	HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis. 2016 , 22, 905-14	13
1062	Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival. 2017 , 26, 414-436	17
1061	Decision support systems for personalized and participative radiation oncology. 2017 , 109, 131-153	79
1060	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. 2017 , 24, 3-15	107
1059	Targeting the Breast Cancer Kinome. 2017 , 232, 53-60	16
1058	A landscape of synthetic viable interactions in cancer. 2018 , 19, 644-655	6
1057	Order Matters: The Order of Somatic Mutations Influences Cancer Evolution. 2017 , 7,	22
1056	Interrogating open issues in cancer precision medicine with patient-derived xenografts. 2017 , 17, 254-268	369
1055	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER ⁺ metastatic breast cancer. 2017 , 49, 444-450	46
1054	Angiopoietin pathway gene expression associated with poor breast cancer survival. 2017 , 162, 191-198	38

1053	[Contribution and challenges of Big Data in oncology]. 2017 , 104, 281-287	1
1052	Genomic insights in gynecologic cancer. 2017 , 41, 8-36	7
1051	Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. 2017 , 7, 40177	8
1050	A PP2A-B55-Mediated Crosstalk between TORC1 and TORC2 Regulates the Differentiation Response in Fission Yeast. 2017 , 27, 175-188	24
1049	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. 2017 , 53, 111-119	97
1048	Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer. 2017 , 22, 71-84	11
1047	Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine. 2017 , 77, 423-433	14
1046	Environmental factors in breast cancer invasion: a mathematical modelling review. 2017 , 49, 172-180	14
1045	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. 2017 , 23, 3802-3812	33
1044	Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells. 2017 , 77, 1575-1585	45
1043	ROR β Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers. 2017 , 77, 1083-1096	71
1042	FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis. 2017 , 162, 243-253	12
1041	Understanding breast cancer - The long and winding road. 2017 , 7, 64-77	97
1040	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. 2017 , 9, 34-44	9
1039	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. 2017 , 175, 91-106	136
1038	The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin. 2017 , 118, 1639-1647	7
1037	The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer. 2017 , 118, 2559-2570	63
1036	An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. 2017 , 7, 575-585	66

1035	Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. 2017 , 18, 2359-2372	39
1034	Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. 2017 , 7, 43813	15
1033	A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. 2017 , 31, 353-369	105
1032	Prediction of years of life after diagnosis of breast cancer using omics and omic-by-treatment interactions. 2017 , 25, 538-544	18
1031	AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. 2017 , 102, 280-283	11
1030	Cancer: a new role for non-canonical Hippo signaling. 2017 , 27, 459-460	2
1029	MINT: a multivariate integrative method to identify reproducible molecular signatures across independent experiments and platforms. 2017 , 18, 128	45
1028	A Transposon-based Analysis Reveals Is Involved in Triple-Negative Breast Cancer. 2017 , 77, 1357-1368	25
1027	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. 2017 , 23, 376-385	82
1026	Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer. 2017 , 30, 28-38	28
1025	Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. 2017 , 114, E2215-E2224	24
1024	Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. 2017 , 140, 2484-2497	24
1023	A population genetics perspective on the determinants of intra-tumor heterogeneity. 2017 , 1867, 109-126	29
1022	Integrin- β identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. 2017 , 114, E2337-E2346	165
1021	SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells. 2017 , 485, 522-528	22
1020	Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients. 2017 , 6, 7-18	15
1019	Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. 2017 , 162, 439-450	34
1018	Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells. 2017 , 162, 465-477	8

1017	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. 2017 , 23, 568-578	78
1016	Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. 2017 , 3, 9	36
1015	Systems Biology and Genomics. 2017 , 1-10	
1014	MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. 2017 , 164, 41-56	22
1013	Pro-necrotic molecules impact local immunosurveillance in human breast cancer. 2017 , 6, e1299302	50
1012	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. 2017 , 31, 553-566	62
1011	NRF2 Induction Supporting Breast Cancer Cell Survival Is Enabled by Oxidative Stress-Induced DPP3-KEAP1 Interaction. 2017 , 77, 2881-2892	91
1010	Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis. 2017 , 116, 1350-1357	54
1009	Thrombospondin-4 mediates TGF- β -induced angiogenesis. 2017 , 36, 5189-5198	68
1008	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. 2017 , 164, 341-348	33
1007	VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. 2017 , 36, 5199-5211	49
1006	G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. 2017 , 1864, 1318-1327	31
1005	Single-cell sequencing deciphers a convergent evolution of copy number alterations from primary to circulating tumor cells. 2017 , 27, 1312-1322	58
1004	Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases. 2017 , 15, 91	6
1003	Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. 2017 , 7, 1089	13
1002	Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. 2017 , 8, 15081	459
1001	Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. 2017 , 10, 19	42
1000	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. 2017 , 77, 3834-3845	58

999	Phenotypic characterisation of breast cancer: the role of CDC42. 2017 , 164, 317-325	18
998	FREQUENT SUBGRAPH MINING OF PERSONALIZED SIGNALING PATHWAY NETWORKS GROUPS PATIENTS WITH FREQUENTLY DYSREGULATED DISEASE PATHWAYS AND PREDICTS PROGNOSIS. 2017 , 22, 402-413	1
997	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. 2017 , 23, 3035-3044	17
996	Meta-Analysis of Genome-Wide Association Studies for Abdominal Aortic Aneurysm Identifies Four New Disease-Specific Risk Loci. 2017 , 120, 341-353	97
995	Identification of MYST3 as a novel epigenetic activator of ER α frequently amplified in breast cancer. 2017 , 36, 2910-2918	29
994	Cooperative genomic alteration network reveals molecular classification across 12 major cancer types. 2017 , 45, 567-582	17
993	An Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer. 2017 , 16, 1967-1978	16
992	Methods to analyze big data in pharmacogenomics research. 2017 , 18, 807-820	8
991	New paradigms for the Hedgehog signaling network in mammary gland development and breast Cancer. 2017 , 1868, 315-332	22
990	Novel therapeutic strategies in the treatment of triple-negative breast cancer. 2017 , 9, 493-511	44
989	In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer. 2017 , 16, 105	15
988	BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. 2017 , 116, 1585-1594	10
987	FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor. 2017 , 28, 2025-2027	4
986	Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1 β in tumor-associated macrophages. 2017 , 6, e1334744	56
985	Targeting the duality of cancer. 2017 , 1,	23
984	Unravelling the complexity of signalling networks in cancer: A review of the increasing role for computational modelling. 2017 , 117, 73-113	8
983	Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. 2017 , 118, 3531-3548	68
982	Somatic Copy Number Alteration-Based Prediction of Molecular Subtypes of Breast Cancer Using Deep Learning Model. 2017 , 57-63	3

981	Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal Evolution. 2017 , 15, 1127-1137	31
980	Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. 2017 , 19, 66	15
979	A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. 2017 , 45, 8269-8281	25
978	A Joint Bayesian Model for Integrating Microarray and RNA Sequencing Transcriptomic Data. 2017 , 24, 647-662	14
977	Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. 2017 , 30, 1086-1099	41
976	Modeling the process of human tumorigenesis. 2017 , 8, 15422	35
975	Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. 2017 , 179, 111-126	40
974	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. 2017 , 96, e6931	3
973	Isolation and Molecular Characterization of Circulating Tumor Cells. 2017 ,	2
972	Molecular Profiling and Significance of Circulating Tumor Cell Based Genetic Signatures. 2017 , 994, 143-167	2
971	MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells. 2017 , 117, 89-101	36
970	Mutational Signatures in Breast Cancer: The Problem at the DNA Level. 2017 , 23, 2617-2629	73
969	CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. 2017 , 9, 1052-1066	53
968	Neonatal Nav1.5 protein expression in normal adult human tissues and breast cancer. 2017 , 213, 900-907	20
967	let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery. 2017 , 36, 5819-5828	23
966	Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. 2017 , 23, 5561-5572	138
965	Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. <i>Nature</i> , 2017 , 544, 250-254	50.4 365
964	CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. 2017 , 45, 6698-6716	75

963	Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine. 2017 , 41, 176-181	15
962	BCIP: a gene-centered platform for identifying potential regulatory genes in breast cancer. 2017 , 7, 45235	12
961	Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries. 2017 , 116, 1088-1091	5
960	Liquid Biopsies in Solid Tumors. 2017 ,	
959	Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications. 2017 , 10, 16	20
958	Detecting gene signature activation in breast cancer in an absolute, single-patient manner. 2017 , 19, 32	6
957	Runx Genes in Breast Cancer and the Mammary Lineage. 2017 , 962, 353-368	10
956	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. 2017 , 30, 952-963	37
955	models in breast cancer research: progress, challenges and future directions. 2017 , 10, 359-371	86
954	Computational approach for deriving cancer progression roadmaps from static sample data. 2017 , 45, e69	8
953	Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis. 2017 , 18, 3143-3154	60
952	Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors. 2017 , 7, 262	15
951	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. 2017 , 19, 44	57
950	CTCs and ctDNA: Two Tales of a Complex Biology. 2017 , 119-137	1
949	Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. 2017 , 36, 4001-4013	70
948	Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery. 2017 , 19, 1091-1098	14
947	Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells. 2017 , 16, 19	17
946	The enigmatic role of RUNX1 in female-related cancers - current knowledge & future perspectives. 2017 , 284, 2345-2362	13

945	Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi. 2017 , 56, 589-597	18
944	Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. 2017 , 389, 2430-2442	394
943	A 16 Yin Yang gene expression ratio signature for ER+/node- breast cancer. 2017 , 140, 1413-1424	7
942	The genetic landscape of breast carcinomas with neuroendocrine differentiation. 2017 , 241, 405-419	35
941	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. 2017 , 23, 2702-2712	51
940	Metabotypes of breast cancer cell lines revealed by non-targeted metabolomics. 2017 , 43, 173-186	19
939	DNA damage repair in breast cancer and its therapeutic implications. 2017 , 49, 156-165	36
938	Principal Graph and Structure Learning Based on Reversed Graph Embedding. 2017 , 39, 2227-2241	40
937	A unified probabilistic framework for robust manifold learning and embedding. 2017 , 106, 627-650	10
936	Molecular classification of breast cancer: what the pathologist needs to know. 2017 , 49, 111-119	54
935	The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells. 2017 , 7, 39873	14
934	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. 2017 , 19, 147-161	11
933	Molecular Classification and Testing of Breast Carcinoma. 2017 , 215-231	
932	Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk. 2017 , 38, 265-268	3
931	The recurrent architecture of tumour initiation, progression and drug sensitivity. 2017 , 17, 116-130	97
930	SLE redefined on the basis of molecular pathways. 2017 , 31, 291-305	8
929	Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase. 2017 , 31, 1939-1957	26
928	Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy. 2017 , 14, 4551-4559	20

927	Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer. 2017 , 19, 885-895	6
926	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. 2017 , 23, 7225-7231	6
925	Triple-negative breast cancer and the potential for targeted therapy. 2017 , 18, 1595-1609	100
924	Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients. 2017 , 7, 12587	15
923	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. 2017 , 23, 1319-1330	77
922	A role for Tau protein in maintaining ribosomal DNA stability and cytidine deaminase-deficient cell survival. 2017 , 8, 693	24
921	How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. 2017 , 2, e000208	33
920	Hedgehog-mesenchyme gene signature identifies bi-modal prognosis in luminal and basal breast cancer sub-types. 2017 , 13, 2615-2624	5
919	Adaptive Multiview Nonnegative Matrix Factorization Algorithm for Integration of Multimodal Biomedical Data. 2017 , 16, 1176935117725727	4
918	PP2A Inactivation Mediated by Haploinsufficiency Promotes Cancer Development. 2017 , 77, 6825-6837	24
917	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017 , 551, 92-94	50.4 643
916	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. 2017 , 49, 1767-1778	186
915	Breast Cancer: Multiple Subtypes within a Tumor?. 2017 , 3, 753-760	124
914	A novel approach for data integration and disease subtyping. 2017 , 27, 2025-2039	78
913	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. 2017 , 117, 1176-1184	10
912	Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials. 2017 , 60, 18-23	28
911	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. 2017 , 9,	112
910	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. 2017 , 49, 1476-1486	255

909	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. 2017 , 109,	40
908	Deconvolution of DNA methylation identifies differentially methylated gene regions on 1p36 across breast cancer subtypes. 2017 , 7, 11594	13
907	Piecing together the puzzle: nanopore technology in detection and quantification of cancer biomarkers. 2017 , 7, 42653-42666	11
906	G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. 2017 , 16, 2146-2155	12
905	Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer. 2017 , 8, 56-65	10
904	DIP2C expression in breast cancer and its clinical significance. 2017 , 213, 1394-1399	6
903	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. 2017 , 8, 606	60
902	Studies of Cancer Heterogeneity Using PDX Models. 2017 , 59-69	
901	Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. 2017 , 5, 816-826	187
900	An Optimal Mean Based Block Robust Feature Extraction Method to Identify Colorectal Cancer Genes with Integrated Data. 2017 , 7, 8584	2
899	A signal-based method for finding driver modules of breast cancer metastasis to the lung. 2017 , 7, 10023	3
898	Precision Oncology: The Road Ahead. 2017 , 23, 874-898	71
897	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. 2017 , 3, 29	27
896	State of the evidence 2017: an update on the connection between breast cancer and the environment. 2017 , 16, 94	93
895	HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology. 2017 , 27, 1573-1588	52
894	Can photoacoustic imaging quantify surface-localized J-aggregating nanoparticles?. 2017 , 22, 76008	2
893	Next-Generation Proteomics and Its Application to Clinical Breast Cancer Research. 2017 , 187, 2175-2184	21
892	Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. 2017 , 187, 2152-2162	114

891	The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. 2017 , 187, 2139-2151	78
890	Big data in cancer genomics. 2017 , 4, 78-84	11
889	Aquatic animals promote antibiotic resistance gene dissemination in water via conjugation: Role of different regions within the zebra fish intestinal tract, and impact on fish intestinal microbiota. 2017 , 26, 5318-5333	47
888	SOX11 promotes invasive growth and ductal carcinoma in situ progression. 2017 , 243, 193-207	27
887	Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease. 2017 , 10, 699-706	4
886	Functional importance of PP2A regulatory subunit loss in breast cancer. 2017 , 166, 117-131	15
885	Dysregulation of Blimp1 transcriptional repressor unleashes p130Cas/ErbB2 breast cancer invasion. 2017 , 7, 1145	14
884	Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. 2017 , 7, 5568	21
883	Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. 2017 , 77, 651-659	12
882	MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. 2017 , 8, e2973	53
881	Transcription factor Sp1 is necessary and functional in regulating expression of oncogene ZNF703. 2017 , 39, 1107-1115	
880	Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors. 2017 , 77, 5395-5408	16
879	p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. 2017 , 45, 11056-11069	41
878	Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. 2017 , 6, e1356142	19
877	Large Scale Medical Data Mining for Accurate Diagnosis: A Blueprint. 2017 , 157-176	13
876	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. 2017 , 7, 1168-1183	38
875	The cell-of-origin dictates the genomic landscape of breast cancers. 2017 , 4, e1338931	1
874	Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. 2017 , 166, 593-601	11

873	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. 2017 , 18, 1360-1372	263
872	Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. 2018 , 25, 828-840	53
871	Identification of cancer genes that are independent of dominant proliferation and lineage programs. 2017 , 114, E11276-E11284	13
870	Resistance to Targeted Therapies in Breast Cancer. 2017 ,	
869	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. 2017 , 3, 48	38
868	The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer. 2017 , 9, 210-216	
867	miR-500a-5p regulates oxidative stress response genes in breast cancer and predicts cancer survival. 2017 , 7, 15966	30
866	Targeting immune checkpoints in breast cancer: an update of early results. 2017 , 2, e000255	79
865	Distinct B subunits of PP2A regulate the NF- κ B signalling pathway through dephosphorylation of IKK β and RelA. 2017 , 591, 4083-4094	19
864	Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. 2017 , 8, 1669	36
863	Targeting the CDK4/6 Pathway in Breast Cancer. 2017 , 807-817	
862	Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer. 2017 , 44, 66-84	7
861	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. 2017 , 8, 1324	314
860	Identification and characterization of a metastatic suppressor BRMS1L as a target gene of p53. 2017 , 108, 2413-2421	10
859	Breast Cancer Genomics. 2017 , 149-156	
858	Fundamental Pathways in Breast Cancer 3: Estrogen Biology. 2017 , 19-26	
857	Mouse Models of Breast Cancer: Deceptions that Reveal the Truth. 2017 , 49-60	
856	Germline copy number variations are associated with breast cancer risk and prognosis. 2017 , 7, 14621	31

855	An Integrative Approach for Identifying Network Biomarkers of Breast Cancer Subtypes Using Genomic, Interactomic, and Transcriptomic Data. 2017 , 24, 756-766	3
854	The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. 2017 , 18, 1331-1351	52
853	Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers - initial evidence of an oncogenic role for CHD7. 2017 , 11, 1348-1360	17
852	First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease. 2017 , 155-176	1
851	Predicting treatment resistance and relapse through circulating DNA. 2017 , 34 Suppl 1, S31-S35	15
850	ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis. 2017 , 13, 1386-1403	86
849	An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. 2017 , 8, e2932	55
848	Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. 2017 , 59, 22-32	29
847	Patient-Derived Xenograft Models of Human Cancer. 2017 ,	5
846	Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer. 2017 , 77, 4673-4683	21
845	Segmentum: a tool for copy number analysis of cancer genomes. 2017 , 18, 215	7
844	The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion. 2017 , 17, 329	9
843	HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells. 2017 , 16, 38	28
842	Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. 2017 , 10, 89	43
841	Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). 2017 , 34 Suppl 1, S27-S30	64
840	Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers. 2017 , 8, e2899	8
839	Discovery of putative breast cancer antigens using an integrative platform of genomics-driven immunoproteomics. 2017 , 17, 1600318	5
838	Integrative cancer genomics: models, algorithms and analysis. 2017 , 11, 392-406	1

837	Research needs in breast cancer. 2017 , 28, 208-217	47
836	PIN1 in breast development and cancer: a clinical perspective. 2017 , 24, 200-211	25
835	The molecular basis of breast cancer pathological phenotypes. 2017 , 241, 375-391	62
834	Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium. 2017 , 36, 1793-1803	22
833	Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer. 2016 , 13, 42-55	17
832	Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. 2017 , 16, 239-250	12
831	Breast cancer. 2017 , 389, 1134-1150	923
830	An algorithm for direct causal learning of influences on patient outcomes. 2017 , 75, 1-15	7
829	Multimodal, high-dimensional, model-based, Bayesian inverse problems with applications in biomechanics. 2017 , 329, 91-125	8
828	Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. 2017 , 161, 41-50	11
827	Stratified, precision or personalised medicine? Cancer services in the 'real world' of a London hospital. 2017 , 39, 143-158	64
826	Pathology and Molecular Pathology of Breast Cancer. 2017 , 173-231	0
825	Brain Structure Biomarkers in the Psychosis Biotypes: Findings From the Bipolar-Schizophrenia Network for Intermediate Phenotypes. 2017 , 82, 26-39	86
824	Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells. 2017 , 36, 1276-1286	44
823	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. 2017 , 30, 69-84	34
822	Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors. 2017 , 77, 175-186	15
821	miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. 2017 , 23, 1091-1103	79
820	Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. 2017 , 241, 350-361	49

819	Cellular responses to replication stress: Implications in cancer biology and therapy. 2017 , 49, 9-20	10
818	Identification of clinically predictive metagenes that encode components of a network coupling cell shape to transcription by image-omics. 2017 , 27, 196-207	19
817	Sparse multivariate factor analysis regression models and its applications to integrative genomics analysis. 2017 , 41, 70-80	5
816	Breast Pathology. 2017 ,	1
815	Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?. 2017 , 43, 909-920	27
814	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. 2017 , 70, 456-465	9
813	Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. 2017 , 86, 297-307	172
812	Un lien entre normalisation de l'angiogénèse et stimulation de l'immunité antitumorale. 2017 , 19, 404-406	
811	Cyclin E Deregulation and Genomic Instability. 2017 , 1042, 527-547	24
810	A stacked generalization method for disease progression prediction. 2017 ,	1
809	Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. 2017 , 1026, 59-104	32
808	Genomic regression analysis of coordinated expression. 2017 , 8, 2187	12
807	A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data. 2017 , 18, 508	79
806	A Bayesian Nonparametric Approach to Testing for Dependence Between Random Variables. 2017 , 12,	18
805	Epigenetic and genetic deregulation in cancer target distinct signaling pathway domains. 2017 , 45, 583-596	12
804	Fatty acid metabolism in breast cancer subtypes. 2017 , 8, 29487-29500	87
803	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. 2017 , 8, 41334-41347	19
802	ERF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. 2017 , 8, 36054-36066	4

801	Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer. 2017 , 8, 54364-54377	24
800	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. 2017 , 1,	7
799	Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study. 2017 , 18, 526	10
798	Transcription Factors in Breast Cancer-Lessons From Recent Genomic Analyses and Therapeutic Implications. 2017 , 107, 223-273	10
797	Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer. 2017 , 22, 1549-1580	7
796	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. 2018 , 52, 424-432	5
795	MYC Deregulation in Primary Human Cancers. 2017 , 8,	174
794	Change of Title: Microarrays Becomes High-Throughput. 2017 , 6,	1
793	Mobilization of Nuclear Copper by Green Tea Polyphenol Epicatechin-3-Gallate and Subsequent Prooxidant Breakage of Cellular DNA: Implications for Cancer Chemotherapy. 2016 , 18,	13
792	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. 2017 , 18,	15
791	Co-Inflammatory Roles of TGF β in the Presence of TNF α Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells. 2017 , 8, 479	20
790	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. 2017 , 8, 1412	54
789	Tumor Heterogeneity in Breast Cancer. 2017 , 4, 227	211
788	Metabolic Footprints and Molecular Subtypes in Breast Cancer. 2017 , 2017, 7687851	33
787	Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer. 2017 , 2017, 5091541	15
786	sCNAPhase: using haplotype resolved read depth to genotype somatic copy number alterations from low cellularity aneuploid tumors. 2017 , 45, e34	4
785	Mesenchymal phenotype of circulating tumor cells is associated with distant metastasis in breast cancer patients. 2017 , 9, 691-700	24
784	Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. 2017 , 7, 2111-2133	9

783	Integrative clustering of multi-level 'omic data based on non-negative matrix factorization algorithm. 2017 , 12, e0176278	57
782	Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+ER ⁺ breast cancer. 2017 , 12, e0179223	7
781	Interactions between the tumor and the blood systemic response of breast cancer patients. 2017 , 13, e1005680	13
780	A network diffusion approach to inferring sample-specific function reveals functional changes associated with breast cancer. 2017 , 13, e1005793	10
779	Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency. 2017 , 13, e1006853	32
778	Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. 2017 , 17, 727	21
777	Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer. 2017 , 15, 199	19
776	The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. 2017 , 19, 99	38
775	Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. 2017 , 19, 113	3
774	miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. 2017 , 19, 133	87
773	GPER mediates the angiocrine actions induced by IGF1 through the HIF-1 α /VEGF pathway in the breast tumor microenvironment. 2017 , 19, 129	42
772	"UPRegulation" of CD47 by the endoplasmic reticulum stress pathway controls anti-tumor immune responses. 2017 , 5, 26	15
771	Subtype identification from heterogeneous TCGA datasets on a genomic scale by multi-view clustering with enhanced consensus. 2017 , 10, 75	10
770	Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. 2017 , 19, 112	50
769	Associations of two-pore domain potassium channels and triple negative breast cancer subtype in The Cancer Genome Atlas: systematic evaluation of gene expression and methylation. 2017 , 10, 475	15
768	Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. 2017 , 7, 15742	7
767	Inflammation, phagocytosis and cancer: another step in the CD47 act. 2017 , 9, 2279-2282	4
766	Triple-negative breast cancer: is there a treatment on the horizon?. 2017 , 8, 1913-1924	176

765	Improvement in prediction of prostate cancer prognosis with somatic mutational signatures. 2017 , 8, 3261-3267	14
764	Tissue Factor promotes breast cancer stem cell activity in vitro. 2017 , 8, 25915-25927	10
763	Mammary gland stem cells and their application in breast cancer. 2017 , 8, 10675-10691	11
762	The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers. 2017 , 8, 4501-4519	17
761	Statistical Consideration in Predictive and Prognostic Markers. 2017 , 245-255	
760	Tumor Heterogeneity. 2017 , 37-55	4
759	Integrative analysis of CXCR4/CXCL12 axis gene expression alterations in breast cancer and its prognostic relevance. 2018 , 11, 6-11	2
758	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. 2021 , 12, 6276	10
757	Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach. 2021 , 41,	1
756	Functional annotation of breast cancer risk loci: current progress and future directions. 2021 ,	1
755	Calsequestrin 2 overexpression in breast cancer increases tumorigenesis and metastasis by modulating the tumor microenvironment. 2021 ,	0
754	Prognostic Value and Clinical Significance of LIPH in Breast Cancer. 2021 , 14, 7613-7623	0
753	Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. 2021 , 60, 230-237	
752	Identification of novel mechanistically distinct endotypes of pandemic influenza-associated acute respiratory failure.	
751	Directionally dependent multi-view clustering using copula model. 2020 , 15, e0238996	
750	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa.	
749	Accurate Prediction of Breast Cancer Survival through Coherent Voting Networks with Gene Expression Profiling.	
748	Impact of germline and somatic cell cycle checkpoint kinase mutations on breast cancer presentation and prognosis.	

747	Stromal Oncostatin M axis promotes breast cancer progression.	
746	E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.	0
745	Multi-resolution characterization of molecular taxonomies in bulk and single-cell transcriptomics data.	0
744	VGLL1-directed TEAD activation drives endocrine therapy resistance in estrogen receptor positive breast cancer.	
743	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).	
742	T-ReCS: stable selection of dynamically formed groups of features with application to prediction of clinical outcomes. 2015 , 431-42	8
741	Unsupervised feature construction and knowledge extraction from genome-wide assays of breast cancer with denoising autoencoders. 2015 , 132-43	43
740	Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine. 2015 , 5, 2330-43	17
739	Breast cancer intrinsic subtype classification, clinical use and future trends. 2015 , 5, 2929-43	296
738	Detection of gene copy number alterations in DCIS and invasive breast cancer by QM-FISH. 2016 , 8, 4994-5004	6
737	HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. 2017 , 7, 1213-1226	24
736	PSMB5 plays a dual role in cancer development and immunosuppression. 2017 , 7, 2103-2120	22
735	High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer. 2019 , 11, 6507-6521	22
734	The activation of GPER inhibits cells proliferation, invasion and EMT of triple-negative breast cancer via CD151/miR-199a-3p bio-axis. 2020 , 12, 32-44	15
733	Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer. 2020 , 10, 95-113	22
732	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. 2020 , 10, e035802	1
731	The N-terminal domain of the adaptor protein p140Cap interacts with Tiam1 and controls Tiam1/Rac1 axis. 2020 , 10, 4308-4324	2
730	A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. 2021 , 11, 3611-3627	2

729	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. 2021 , 11, 3628-3644	2
728	Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer. 2021 , 11, 3674-3687	2
727	MELK expression in breast cancer is associated with infiltration of immune cell and pathological complete response (pCR) after neoadjuvant chemotherapy. 2021 , 11, 4421-4437	1
726	Bayesian tensor factorization-drive breast cancer subtyping by integrating multi-omics data. 2021 , 125, 103958	0
725	Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.. 2022 , 18, 229-241	
724	Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways. 2021 , 16, e0260327	3
723	Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype. 2021 , 17, e1009876	0
722	SLC7A5 is linked to increased expression of genes related to proliferation and hypoxia in estrogen-receptor-positive breast cancer. 2022 , 47,	0
721	ZHX2 promotes HIF1 α oncogenic signaling in triple-negative breast cancer. 2021 , 10,	2
720	Patient Similarity in the Era of Precision Medicine: A Philosophical Analysis. 1	0
719	Novel Insights into the Prognosis and Immunological Value of the SLC35A (Solute Carrier 35A) Family Genes in Human Breast Cancer.. 2021 , 9,	1
718	Vitamin D and Breast Cancer: Mechanistic Update.. 2021 , 5, e10582	4
717	UK Women's Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study. 2021 , 13,	0
716	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. 2021 , 5,	0
715	MiR-195 and Its Target SEMA6D Regulate Chemoresponse in Breast Cancer. 2021 , 13,	2
714	Inner nuclear membrane protein TMEM201 promotes breast cancer metastasis by positive regulating TGF β signaling. 2021 ,	4
713	Copy number heterogeneity identifies ER+ breast cancer patients with adverse outcome after adjuvant endocrine therapy.	
712	Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer. 2021 , 13,	0

- 711 Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. **2021**, 10, 77 0
- 710 Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGF β /PI3K/AKT pathways. **2021**, 23, 107 0
- 709 Cohort and Trajectory Analysis in Multi-Agent Support Systems for Cancer Survivors. **2021**, 45, 109 0
- 708 Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. **2021**, 5, 2
- 707 Genomic hallmarks of cellular dormancy in cancer and therapeutic implications.
- 706 The role of KPNA2 mutations in breast cancer prognosis: A survey of publicly available databases.
- 705 Coordinated regulation of WNT/ β -catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits. **2021**, 21, 1296 0
- 704 Genome-Wide Copy Number Variation of Circulating Cell-Free DNA As a Biomarker in Head and Neck Cancer Patients Treated With Immunotherapy.
- 703 Overlap between nutrient metabolism and chemotherapy detoxification in triple negative breast cancer. **2021**, 80,
- 702 Hierarchical Ridge Regression for Incorporating Prior Information in Genomic Studies. **2021**, 1-17
- 701 Clinical Observation of the Treatment of Triple Negative Breast Cancer with the Combination of the Tislelizumab and the Chemotherapy. **2021**, 11, 5717-5722
- 700 Similarity Fusion via Exploiting High Order Proximity for Cancer Subtyping.. **2021**, PP, 0
- 699 Involvement of Par-4 in Breast Cancer. **2021**, 113-131
- 698 Harnessing Antitumor CD4 T Cells for Cancer Immunotherapy.. **2022**, 14, 3
- 697 Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. **2022**, 75, 103801 3
- 696 Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy.. **2022**, 14, 1
- 695 When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.. **2022**, 2
- 694 C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer.. **2022**, 13, 69 2

693	Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer.. 2022 , 1	0
692	Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.. 2022 , 529, 153-167	1
691	Comprehensive analysis of the gene family functions in breast cancer.. 2020 , 9, 6369-6382	1
690	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. 2020 , 10, e035802	1
689	RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts.	
688	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making.. 2021 , 11,	1
687	Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine. 2021 ,	1
686	Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma.. 2022 , 185, 299-310.e18	14
685	A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.. 2022 , 1	0
684	Knockdown of NAA25 Suppresses Breast Cancer Progression by Regulating Apoptosis and Cell Cycle.. 2021 , 11, 755267	0
683	GNOSIS: an R Shiny app supporting cancer genomics survival analysis with cBioPortal. 5, 8	
682	KDM6A depletion in breast epithelial cells leads to reduced sensitivity to anticancer agents and increased TGF- β activity.. 2022 ,	0
681	Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis.. 2022 , 12, 1463	0
680	Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature.. 2022 , 12, 1317	0
679	Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors.. 2022 , 38, 110278	2
678	In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis.. 2022 ,	1
677	CBioExplorer: a web and standalone application for screening, validation, and annotation of cancer survival related biomarkers from molecular level to clinical settings.	
676	STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts.. 2022 ,	4

675	Detecting molecular subtypes from multi-omics datasets using SUMO.. 2022 , 2, 100152-100152	1
674	Hormonal and Targeted Treatments in Breast Cancer. 2022 , 443-463	2
673	Vulnerability of Triple-Negative Breast Cancer to Saponin Formosanin C-Induced Ferroptosis.. 2022 , 11,	0
672	ABI1-based expression signature predicts breast cancer metastasis and survival.. 2021 ,	0
671	High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level.. 2022 , 18, 1120-1133	2
670	Complexity against current cancer research - are we on the wrong track?. 2021 ,	4
669	New insights in the interaction of FGF/FGFR and steroid receptor signaling in breast cancer.. 2022 ,	1
668	mTORC2 Drives ZFX-mediated Ganglioside Biosynthesis to Promote Breast Cancer Progression.	
667	Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer.. 2022 , 11, 2020984	4
666	Analysis of cancer omics data: a selective review of statistical techniques.. 2022 ,	0
665	Pathogenesis of Triple-Negative Breast Cancer.. 2022 , 17, 181-204	10
664	Mitochondrial-nuclear epistasis underlying phenotypic variation in breast cancer pathology.. 2022 , 12, 1393	0
663	An mRNA expression-based signature for oncogene-induced replication-stress.. 2022 ,	0
662	Neurogenesis and angiogenesis are associated features of aggressive breast cancer.	
661	Characterized the diversity of ABCB1 subtypes in immunogenomic landscape for predicting the drug response in breast cancer.. 2022 ,	0
660	Robust nonparametric integrative analysis to decipher heterogeneity and commonality across subgroups using sparse boosting.. 2022 ,	0
659	Multi-Omics Profiling Suggesting Intratumoral Mast Cells as Predictive Index of Breast Cancer Lung Metastasis.. 2021 , 11, 788778	
658	AXL-TBK1 driven nuclear AKT3 promotes metastasis.	

- 657 A biphasic Deep Semi-supervised framework for Suptype Classification and biomarker discovery.
- 656 Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures.. **2022**, 13, 805184 ○
- 655 Classification of Breast Cancer. **2022**, 71-85
- 654 The prospects of precision psychiatry.. **2022**, 42, 193 ○
- 653 Evaluating statistical approaches to define clonal origin of tumours using bulk DNA sequencing: context is everything.. **2022**, 23, 43 1
- 652 Transcriptional determinants of cancer immunotherapy response and resistance.. **2022**, ○
- 651 Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.. **2022**, 17, 101339
- 650 as a potential biomarker and therapeutic target for breast cancer patients.. **2022**, 19, 434-445 ○
- 649 Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. **2022**, 1 ○
- 648 A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.. **2022**, 12, 2211
- 647 Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.. **2022**, 192, 529 1
- 646 Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.. **2022**, 14, ○
- 645 Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature.. **2022**, 17, e0261035 ○
- 644 Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer.. **2022**, 7, ○
- 643 Aberrant epigenetic and transcriptional events associated with breast cancer risk.. **2022**, 14, 21 1
- 642 cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment.. **2022**, 41, 54 ○
- 641 Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.. **2021**, 23, 114 ○
- 640 HLA Class II Histocompatibility Antigen α Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer.. **2021**, 13, ○

- 639 An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progression.. **2021** 1
- 638 MFmap: A semi-supervised generative model matching cell lines to tumours and cancer subtypes.. **2021**, 16, e0261183 0
- 637 Multi-omic machine learning predictor of breast cancer therapy response. *Nature*, **2021**, 504 15
- 636 Prognostic role of EGR1 in breast cancer: a systematic review. **2021**, 54, 497-504
- 635 New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling. **2021**, 11, 5214-5232 1
- 634 Development of KAM score to predict metastasis and worse survival in breast cancer. **2021**, 11, 5388-5401
- 633 Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC). **2021**, 11, 5743-5755
- 632 **2021**,
- 631 Multi-omic Approaches to Improve Cancer Diagnosis, Prognosis, and Therapeutics. **2022**, 411-433
- 630 Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer.. **2022**, 4, zcac008 0
- 629 Heterogeneity and function of macrophages in the breast during homeostasis and cancer.. **2022**, 367, 149-182 1
- 628 [Is there a claudin-low phenotype of breast cancer?]. **2022**, 84, 45-49 0
- 627 Glycoproteomics Identifies Plexin-B3 as Targetable Cell Surface Protein Required for Growth and Invasion of Triple Negative Breast Cancer Cells.
- 626 Artificial Intelligence for Precision Oncology.. **2022**, 1361, 249-268 2
- 625 Early Breast Cancer Evolution by Autosomal Broad Copy Number Alterations.. **2022**, 2022, 9332922 0
- 624 Classification of Breast Cancer Nottingham Prognostic Index Using High-Dimensional Embedding and Residual Neural Network.. **2022**, 14, 4
- 623 IDNetwork: A deep illness-death network based on multi-state event history process for disease prognostication.. **2022**, 41, 1573-1598
- 622 Using clinical decision support systems in breast cancer treatment: a critical review.

621	Multiomics Topic Modeling for Breast Cancer Classification.. 2022 , 14,	0
620	A comprehensive analysis of the diagnostic and prognostic value associated with the family members in breast cancer.. 2022 , 11, 389-411	0
619	Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency.. 2022 , 10, 845950	0
618	Transcriptional Factor Repertoire of Breast Cancer in 3D Cell Culture Models.. 2022 , 14,	1
617	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. 2022 , 13, 896	4
616	FAM83A is a potential biomarker for breast cancer initiation.. 2022 , 10, 8	0
615	Cxcl10 chemokine induces migration of ING4-deficient breast cancer cells via a novel crosstalk mechanism between the Cxcr3 and Egfr receptors. 2021 , MCB0038221	1
614	PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer.. 2022 , 8, 24	1
613	Characterisation of the Stromal Microenvironment in Lobular Breast Cancer.. 2022 , 14,	1
612	Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.. 2022 , 38, 110418	0
611	Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer.. 2022 , 8, 26	0
610	Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ER β Positive Breast Cancer.. 2022 , 14,	0
609	Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics.. 2022 , 82, 1174-1192	3
608	Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.. 2022 , 1	1
607	spongEffects: ceRNA modules offer patient-specific insights into the miRNA regulatory landscape.	0
606	CHA1: A New Combinatorial Therapy That Reciprocally Regulates Wnt and JAK/STAT/Interferon Signaling to Re-program Breast Tumors and the Tumor-Resident Landscape.	
605	Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer.. 2022 , 15, 19	0
604	Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.. 2022 , 12, 856974	4

603	High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers.. 2022 , 11,	
602	The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients.. 2022 , 12, 835626	
601	SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA.. 2022 , 10, 853596	0
600	GIT1 protects against breast cancer growth through negative regulation of Notch.. 2022 , 13, 1537	0
599	The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature.. 2022 , 10,	0
598	INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.. 2022 , 24, 18	0
597	Impact of duration of neoadjuvant aromatase inhibitors on molecular expression profiles in estrogen receptor positive breast cancers.. 2021 ,	0
596	Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics Analysis.. 2022 , 27,	0
595	Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.. 2022 ,	
594	vWCluster: Vector-valued optimal transport for network based clustering using multi-omics data in breast cancer.. 2022 , 17, e0265150	0
593	Tissue-resident FOLR2 macrophages associate with CD8 T'cell infiltration in human breast cancer.. 2022 ,	4
592	Pioneer factors as master regulators of the epigenome and cell fate.. 2022 ,	4
591	Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer. 2022 , 2022, 1-14	1
590	BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer.. 2022 , 14,	0
589	A comprehensive analysis of immune landscape of Indian triple negative breast cancer.	
588	Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study.. 2022 ,	0
587	BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.. 2022 , 1	1
586	Tumor cell intrinsic and extrinsic features predict' prognosis in estrogen receptor positive breast cancer.. 2022 , 18, e1009495	

585	MiR-206 conjugated gold nanoparticle based targeted therapy in breast cancer cells.. 2022 , 12, 4713	0
584	A multimodal deep learning infused with artificial algae algorithm [An architecture of advanced E-health system for cancer prognosis prediction. 2022 ,	
583	Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFB2 signaling pathway.. 2022 , 13, 195	0
582	ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.. 2022 , 22, 226	0
581	LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.. 2022 ,	2
580	Reducing N6AMT1-mediated 6mA DNA modification promotes breast tumor progression via transcriptional repressing cell cycle inhibitors.. 2022 , 13, 216	0
579	classifieR a flexible interactive cloud-application for functional annotation of cancer transcriptomes.. 2022 , 23, 114	
578	Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.. 2022 ,	7
577	Survival analysis of pathway activity as a prognostic determinant in breast cancer.. 2022 , 18, e1010020	0
576	High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.. 2022 , 193, 49	1
575	High RRM2 expression has poor prognosis in specific types of breast cancer.. 2022 , 17, e0265195	0
574	TRPV Family Ion Channels in the Mammary Epithelium: Role in Normal Tissue Homeostasis and along Breast Cancer Progression.	
573	MCL-1 is a clinically targetable vulnerability in breast cancer.. 2022 , 1-17	2
572	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.. 2022 , 20, 105	2
571	Early detection of cancer.. 2022 , 375, eaay9040	27
570	Analysis of Yes-Associated Protein-1 (YAP1) Target Gene Signature to Predict Progressive Breast Cancer.. 2022 , 11,	0
569	High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.. 2022 ,	
568	Role of the Cisternal Maturation Machinery in Glycan Synthesis and Oncogenesis.. 2022 , 10, 842448	0

567	Chromatin accessibility and transcription factors in invasive lobular and ductal breast cancers.	
566	NSMCE2, a Novel Super-Enhancer Regulated Gene, is Linked to Poor Prognosis and Therapy Resistance in Breast Cancer.	
565	Data integration and mechanistic modelling for breast cancer biology: current state and future directions. 2022 , 100350	1
564	NRF2 drives an oxidative stress response predictive of breast cancer.. 2022 ,	0
563	Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer.. 2022 , 14,	0
562	Stromal Oncostatin M cytokine promotes breast cancer progression by reprogramming the tumour microenvironment.. 2022 ,	3
561	The roles of G3BP1 in human diseases (review).. 2022 , 821, 146294	3
560	Toehold switch based biosensors for sensing the highly trafficked rosewood .. 2022 , 7, 791-801	0
559	BroadSurv: A Novel Broad Learning System-based Approach for Survival Analysis. 2021 ,	0
558	Unsupervised construction of computational graphs for gene expression data with explicit structural inductive biases. 2021 ,	
557	Outcome-guided sparse K-means for disease subtype discovery via integrating phenotypic data with high-dimensional transcriptomic data. 2022 , 71, 352-375	
556	Targeting Metabolic Pathways of Myeloid Cells Improves Cancer Immunotherapy.. 2021 , 9, 747863	1
555	ENTREP/FAM189A2 encodes a new ITCH ubiquitin ligase activator that is downregulated in breast cancer.. 2021 , e51182	0
554	Zebrafish xenografts to isolate unique human breast cancer metastatic cell populations.	
553	Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.. 2021 ,	0
552	Identifying Cancer Subtypes Using a Residual Graph Convolution Model on a Sample Similarity Network.. 2021 , 13,	0
551	Three-Dimensional Genome Organization in Breast and Gynecological Cancers: How Chromatin Folding Influences Tumorigenic Transcriptional Programs.. 2021 , 11,	1
550	NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. 2021 , 33, 2380-2397.e9	10

549	Determination of signature genes of breast cancer subtypes evaluated by clinical criteria using biclustering algorithm. 2021 ,	
548	Multi-omics Topic Modeling for Breast Cancer Classification.	
547	Artificial Intelligence (AI) in Drugs and Pharmaceuticals. 2021 ,	1
546	Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer.. 2021 , 13,	0
545	Germline Allelic Expression of Genes at 17q22 Locus Associates with Risk of Breast Cancer.	
544	The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.. 2021 , 40, 397	1
543	B cell-related gene signature and cancer immunotherapy response.. 2021 ,	1
542	Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression. 2021 , 9,	0
541	Validation of cluster analysis results on validation data: A systematic framework.	3
540	Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells. 2021 ,	0
539	Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis.. 2021 , 12, 7311	12
538	Can Systems Biology Advance Clinical Precision Oncology?. 2021 , 13,	1
537	TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer.. 2021 , 10,	0
536	Nuclear pore protein NUP210 depletion suppresses metastasis through heterochromatin-mediated disruption of tumor cell mechanical response.. 2021 , 12, 7216	3
535	Molecular analysis of TCGA breast cancer histologic types.. 2021 , 1,	2
534	. 2021 , 108, 11S1-11S7	0
533	Phosphatidylserine Synthase PTSS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation.. 2022 , 82, 1617-1632	1
532	Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern.. 2022 , 12, 830124	0

- 531 Octreotide acetate enhanced radio sensitivity and induced apoptosis in MCF7 breast cancer cell line. **2022**, 15, 193-198
- 530 Challenges and Gaps in Clinical Trial Genomic Data Management.. **2022**, 6, e2100193
- 529 Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome.. **2022**, 119, e2107394119 5
- 528 Regulation of XPO5 phosphorylation by PP2A in hepatocellular carcinoma.. **2022**, 3, e125
- 527 ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.. **2022**, 13, 2011 0
- 526 'On the Spot' Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging.. **2022**, 3
- 525 Mesenchymal tumor cells drive adaptive resistance of Trp53 breast tumor cells to inactivated mutant Kras.. **2022**,
- 524 References. **2022**, 313-334
- 523 MoSBI: Automated signature mining for molecular stratification and subtyping.. **2022**, 119, e2118210119 1
- 522 Computationally repurposing drugs for breast cancer subtypes using a network-based approach.. **2022**, 23, 143 1
- 521 Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models.. **2022**, 82, 1658-1668 1
- 520 Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer.. **2022**, 15, 4037-4052 0
- 519 Editorial: Current Status and Future Challenges of Biobank Data Analysis.. **2022**, 13, 882611
- 518 Breast tumor microenvironment structures are associated with genomic features and clinical outcome.. **2022**, 4
- 517 PD-L1 and ICOSL discriminate human Secretary and Helper dendritic cells in cancer, allergy and autoimmunity.. **2022**, 13, 1983 2
- 516 Ribosome assembly factor PNO1 is associated with progression and promotes tumorigenesis in triple-negative breast cancer.. **2022**, 47, 0
- 515 Notes. 179-189
- 514 DataSheet1.zip. **2018**,

513 Table_1.xlsx. **2020**,

512 Data_Sheet_1.xlsx. **2020**,

511 Data_Sheet_2.pdf. **2020**,

510 Presentation_1.pdf. **2019**,

509 Image_1.PDF. **2018**,

508 Image_2.PDF. **2018**,

507 Image_3.PDF. **2018**,

506 Image_4.PDF. **2018**,

505 Table_1.XLSX. **2018**,

504 Table_2.XLSX. **2018**,

503 Table_3.XLSX. **2018**,

502 Table_4.XLSX. **2018**,

501 Table_5.XLSX. **2018**,

500 Table_6.XLSX. **2018**,

499 Image_1.JPEG. **2019**,

498 Image_2.JPEG. **2019**,

497 Table_1.XLSX. **2019**,

496 Image_1.TIF. **2020**,

495 Image_2.TIF. 2020,

494 Image_3.TIF. 2020,

493 Image_4.TIF. 2020,

492 Table_1.docx. 2020,

491 Table_2.XLSX. 2020,

490 Image_1.TIFF. 2018,

489 Table_1.XLSX. 2018,

488 Data_Sheet_1.pdf. 2021,

487 DataSheet_1.docx. 2019,

486 Image_1.TIF. 2020,

485 Image_2.TIF. 2020,

484 Image_1.TIF. 2019,

483 Image_2.TIF. 2019,

482 Image_3.TIF. 2019,

481 Image_4.TIF. 2019,

480 Image_5.TIF. 2019,

479 Image_6.tif. 2019,

478 Table_1.xlsx. 2019,

477 Image_1.JPEG. 2019,

476 Image_2.JPEG. 2019,

475 Image_3.JPEG. 2019,

474 Data_Sheet_1.PDF. 2020,

473 Data_Sheet_1.pdf. 2020,

472 Image_1.tif. 2020,

471 Image_2.tif. 2020,

470 Image_3.tif. 2020,

469 Image_4.tif. 2020,

468 Table_1.docx. 2020,

467 Table_2.docx. 2020,

466 Table_3.docx. 2020,

465 Table_4.xlsx. 2020,

464 Image_1.TIFF. 2020,

463 Image_2.TIFF. 2020,

462 Table_1.XLS. 2020,

461 Table_2.XLS. 2020,

460 Data_Sheet_1.pdf. 2020,

459 Data_Sheet_2.xlsx. 2020,

458 Data_Sheet_1.PDF. 2020,

457 Table_1.XLSX. 2020,

456 Table_2.XLSX. 2020,

455 Image_1.TIF. 2020,

454 Image_2.TIF. 2020,

453 Image_3.TIF. 2020,

452 Image_4.TIF. 2020,

451 Image_5.TIF. 2020,

450 Image_6.TIF. 2020,

449 Image_7.TIF. 2020,

448 Image_8.TIF. 2020,

447 Image_9.TIF. 2020,

446 Table_1.DOCX. 2020,

445 Table_2.DOCX. 2020,

444 Table_3.docx. 2020,

443 Data_Sheet_1.pdf. 2020,

442 Table_1.XLSX. 2020,

441 Table_2.XLSX. 2020,

440 Table_3.XLSX. 2020,

439 Table_4.XLSX. 2020,

438 Table_5.XLSX. 2020,

437 Table_6.XLSX. 2020,

436 Table_7.XLSX. 2020,

435 Data_Sheet_1.docx. 2020,

434 Table_1.doc. 2020,

433 Table_2.xlsx. 2020,

432 Data_Sheet_1.zip. 2018,

431 Image_1.jpg. 2020,

430 Image_2.jpg. 2020,

429 Image_3.tif. 2020,

428 Image_4.jpg. 2020,

427 Image_5.jpg. 2020,

426 Table_1.DOCX. 2020,

425 Table_2.DOCX. 2020,

424 Table_3.DOCX. 2020,

423	Table_4.DOCX. 2020,	
422	Table_5.DOCX. 2020,	
421	Table_6.DOCX. 2020,	
420	Data_Sheet_1.docx. 2018,	
419	Image_1.pdf. 2019,	
418	Data_Sheet_1.ZIP. 2018,	
417	Data_Sheet_2.ZIP. 2018,	
416	Data_Sheet_3.ZIP. 2018,	
415	Robust structured heterogeneity analysis approach for high-dimensional data.. 2022,	0
414	CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis.. 2022, 1	1
413	Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs.. 2022,	0
412	CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1.. 2022, 41, 149	2
411	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.. 2022, 14, 25-39	1
410	, a p53-downstream gene, is associated with suppression of breast cancer cell proliferation and better survival.. 2021, 11, 6060-6073	
409	Upregulation of Cyclin B2 () in breast cancer contributes to the development of lymphovascular invasion.. 2022, 12, 469-489	
408	APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.. 2022, 12, 744-762	
407	H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer.. 2022, 12, 793-804	
406	Comprehensive comparison of theranostic nanoparticles in breast cancer.. 2022, 11, 1-27	

405	Neural Survival Clustering: Non-parametric mixture of neural networks for survival clustering.. 2022 , 174, 92-102	
404	Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing. 25,	
403	Association of Gene Polymorphisms With Breast Cancer Susceptibility: A Meta-Analysis.. 2022 , 8, e2100399	0
402	Identification of Cancer-Associated Fibroblast Subtype of Triple-Negative Breast Cancer.. 2022 , 2022, 6452636	0
401	microRNA-27b regulates hepatic lipase enzyme LIPC and reduces triglyceride degradation during hepatitis C virus infection.. 2022 , 101983	1
400	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.. 2022 , 8, 56	1
399	The Effect of Intratumoral Interrelation among FOXP3+ Regulatory T Cells on Treatment Response and Survival in Triple-Negative Breast Cancer.. 2022 , 14,	
398	Polyamines in cancer: integrating organismal metabolism and antitumour immunity.. 2022 ,	10
397	Stromal p53 Regulates Breast Cancer Development, the Immune Landscape, and Survival in an Oncogene-Specific Manner.. 2022 ,	0
396	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.. 2022 , 8, 57	1
395	Single-cell analysis reveals the Comma-1D cell line as a unique model for mammary gland development and breast cancer.. 2022 , 135,	
394	Comprehensive Landscape of STEAP Family Members Expression in Human Cancers: Unraveling the Potential Usefulness in Clinical Practice Using Integrated Bioinformatics Analysis. 2022 , 7, 64	2
393	A T cell resilience model associated with response to immunotherapy in multiple tumor types.. 2022 ,	1
392	The AMPK-related kinase NUA2 suppresses glutathione peroxidase 4 expression and promotes ferroptotic cell death in breast cancer cells.. 2022 , 8, 253	0
391	CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.. 2022 , 13, 2642	0
390	MicroRNA signature for interpretable breast cancer classification with subtype clue. 2022 , 100042	0
389	Survival stacking with multiple data types using pseudo-observation-based-AUC loss.. 2022 , 1-13	
388	MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. 2022 , 2, 110-130	2

- 387 DPYSL2 interacts with JAK1 to mediate breast cancer cell migration.. **2022**, 221, 0
- 386 PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.. **2022**, 3
- 385 Low expression of PCK2 in breast tumors contributes to better prognosis via inducing senescence of cancer cells.. **2022**, 0
- 384 Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.. **2022**, 0
- 383 Sex-determining Region Y-box transcription factor 13 promotes breast cancer cell proliferation and glycolysis by activating the tripartite motif containing 11-mediated Wnt/ β -catenin signaling pathway. **2022**, 13, 13033-13044 0
- 382 RON (MST1R) and HGFL (MST1) Co-Overexpression Supports Breast Tumorigenesis through Autocrine and Paracrine Cellular Crosstalk. **2022**, 14, 2493 1
- 381 Machine learning enables accurate prediction of breast cancer five-year survival using somatic genomic variants.
- 380 Wnt Signaling in the Breast: From Development to Disease. **2022**, 10, 1
- 379 A human breast atlas integrating single-cell proteomics and transcriptomics. **2022**, 1
- 378 Learning from Small Medical Data - Robust Semi-Supervised Cancer Prognosis Classifier with Bayesian Variational Autoencoder.
- 377 A Spatial Attention Guided Deep Learning System for Prediction of Pathological Complete Response Using Breast Cancer Histopathology Images. 0
- 376 Identifying drivers of breast cancer metastasis in progressively invasive subpopulations of zebrafish-xenografted MDA-MB-231. **2022**, 3,
- 375 Integration of multi-omics data shows downregulation of mismatch repair, purin, and tublin pathways in AR-negative triple-negative chemotherapy-resistant breast tumors.
- 374 XIST loss impairs mammary stem cell differentiation and increases tumorigenicity through Mediator hyperactivation. **2022**, 1
- 373 Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. 12, 2
- 372 High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer. **2022**, 17, e0268799
- 371 Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.
- 370 Identification of a gene signature to assess HSF1 transcriptional activity.

369	Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.	0
368	Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer. 2022 , 22,	1
367	Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. 2022 , 10, 1313	0
366	SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. 2022 , 132,	0
365	Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer. 2022 , 24,	3
364	Prediction of Molecular Subtypes Using Superb Microvascular Imaging and Shear Wave Elastography in Invasive Breast Carcinomas. 2022 ,	
363	Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC). 2022 , 41,	2
362	NF- κ B -dependent secretome of senescent cells can trigger neuroendocrine transdifferentiation of breast cancer cells.	0
361	Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (±) Breast Cancer. 13,	1
360	Glycoproteomics Identifies Plexin-B3 as Targetable Cell Surface Protein Required for Growth and Invasion of Triple Negative Breast Cancer Cells.	
359	Beyond Genetics: Metastasis as an Adaptive Response in Breast Cancer. 2022 , 23, 6271	0
358	Prediction of Breast Cancer Recurrence in Five Years using Machine Learning Techniques and SHAP. 2022 , 441-453	
357	Big data analytics in precision medicine. 2022 , 63-72	
356	Boolean modelling as a logic-based dynamic approach in systems medicine. 2022 , 20, 3161-3172	0
355	Comparisons of Knowledge Graphs and Entity Extraction in Breast Cancer Subtyping Biomedical Text Analysis. 2022 , 249-259	
354	Synthetic lethality-based prediction of cancer treatment response from histopathology images.	
353	Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors. 2022 , 14, 2848	
352	Investigating CENPW as a Novel Biomarker Correlated With the Development and Poor Prognosis of Breast Carcinoma. 13,	0

351	Examples of Inverse Comorbidity between Cancer and Neurodegenerative Diseases: A Possible Role for Noncoding RNA. 2022 , 11, 1930	0
350	Delineation of Pathogenomic Insights of Breast Cancer in Young Women. 2022 , 11, 1927	0
349	Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer.	
348	FGF7 / FGFR2 Δ JunB signalling counteracts the effect of progesterone in luminal breast cancer.	0
347	Breast Cancer Genomics: Primary and Most Common Metastases. 2022 , 14, 3046	
346	GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. 2022 , 8,	0
345	Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness.	1
344	Artificial intelligence and machine learning in precision and genomic medicine. 2022 , 39,	7
343	ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers. 2022 , 18,	0
342	Host CLIC4 expression in the tumor microenvironment is essential for breast cancer metastatic competence. 2022 , 18, e1010271	
341	ECM1 is associated with endocrine resistance in ER+ breast cancers. 1-9	1
340	Evaluation of doxorubicin in three-dimensional culture of breast cancer cells and the response in PI3K/AKT/PTEN signaling pathways: a pilot study. 1-9	
339	Integrated Multi-Omics Analysis Model to Identify Biomarkers Associated With Prognosis of Breast Cancer. 12,	0
338	NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation. 2022 , 14, 2962	1
337	Characterization of gene cluster heterogeneity in single-cell transcriptomic data within and across cancer types. 2022 , 11,	0
336	Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases. 2022 , 8,	0
335	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.	1
334	Prolactin: The Third Hormone in Breast Cancer. 13,	0

- 333 The Role of Peptidyl Arginine Deiminase IV(PADI4) in Cancers. **2022**, 22,
- 332 Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant. **2022**, 8, 0
- 331 Activation Versus Inhibition of IGF1R: A Dual Role in Breast Tumorigenesis. 13, 0
- 330 Molecular and Clinical Characterization of CD80 Expression via Large-Scale Analysis in Breast Cancer. 13,
- 329 Machine Intelligence in Biomedical Data Modeling, Processing, and Analysis. **2022**, 1
- 328 Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. **2022**, 23, 6547 0
- 327 An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. **2022**, 7, 100502 1
- 326 Deep learning-based transcription factor activity for stratification of breast cancer patients. **2022**, 1865, 194838
- 325 MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization. **2022**, 36, 039463202211123
- 324 Use of Imaging Mass Cytometry in Studies of the Tissue Microenvironment. **2022**, 345-364 1
- 323 PP2A is activated by cytochrome c upon formation of a diffuse encounter complex with SET/TAF-1 **2022**, 20, 3695-3707
- 322 Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. **2022**, 13, 1
- 321 Is loss of p53 a driver of ductal carcinoma in situ progression?.
- 320 TAAcGH Suite for Detecting Cancer-Specific Copy Number Changes Using Topological Signatures. **2022**, 24, 896
- 319 The Impact of PIK3R1 Mutations and Insulin/IGF1R Glycolytic Pathway Regulation in Prostate Cancer. OF1-OF15 1
- 318 Role of germline variants in the metastasis of breast carcinomas. **2022**, 13, 843-862
- 317 The Maximum Entropy Principle For Compositional Data.
- 316 Relationship of micro-RNA, mRNA and eIF Expression in Tamoxifen-Adapted MCF-7 Breast Cancer Cells: Impact of miR-1972 on Gene Expression, Proliferation and Migration. **2022**, 12, 916

- 315 Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. **2022**, 4, 693-710 5
- 314 A convolutional neural network model for survival prediction based on prognosis-related cascaded Wx feature selection. 1
- 313 In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. **2022**, 8, 1
- 312 Multiomics technologies: role in disease biomarker discoveries and therapeutics.
- 311 ShapoGraphy: A User-Friendly Web Application for Creating Bespoke and Intuitive Visualisation of Biomedical Data. 2,
- 310 Age-associated differences in the cancer molecular landscape. **2022**, 0
- 309 Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer.
- 308 Single cell multi-omic mapping of subclonal architecture and pathway phenotype in primary gastric and metastatic colon cancers.
- 307 Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. **2022**, 194, 569-575 0
- 306 High PANX1 Expression Leads to Neutrophil Recruitment and the Formation of a High Adenosine Immunosuppressive Tumor Microenvironment in Basal-like Breast Cancer. **2022**, 14, 3369 0
- 305 Pathway Analysis Through Mutual Information. 0
- 304 MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms. **2022**, 11,
- 303 CProtMEDIAS: clustering of amino acid sequences encoded by gene families by MERging and Digitizing Aligned Sequences. **2022**, 23,
- 302 Comparative Analysis of Gene Correlation Networks of Breast Cancer Patients Based on Mutations in TP53. **2022**, 12, 979
- 301 CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. **2022**, 14, 3361 1
- 300 Penalized estimation of a class of single-index varying-coefficient models for integrative genomic analysis.
- 299 Dynamic Co-Evolution of Cancer Cells and Cancer-Associated Fibroblasts: Role in Right- and Left-Sided Colon Cancer Progression and Its Clinical Relevance. **2022**, 11, 1014 0
- 298 PregGAN: A prognosis prediction model for breast cancer based on conditional generative adversarial networks. **2022**, 107026 0

- 297 The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis. **2022**, 176, 103757 1
- 296 Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer. **2022**, 172, 146-157
- 295 Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.
- 294 Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer.. 2
- 293 Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer. 13, 0
- 292 Contrast Subgraphs Allow Comparing Homogeneous and Heterogeneous Networks Derived from Omics Data.
- 291 Poziotinib Inhibits HER2-Mutant Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. **2022**, 82, 2928-2939 0
- 290 Analyzing biomarker discovery: Estimating the reproducibility of biomarker sets. **2022**, 17, e0252697
- 289 CYP2S1 and CYP2W1 expression is associated with patient survival in breast cancer.
- 288 Decreased DNA damage and improved p53 specificity of RITA analogs.
- 287 Deep Multimodal Graph-Based Network for Survival Prediction from Highly Multiplexed Images and Patient Variables.
- 286 AKT1 Transcriptomic Landscape in Breast Cancer Cells. **2022**, 11, 2290
- 285 CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope. **2022**, 22, 0
- 284 Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas. **2022**, 24, 0
- 283 Deep Learning-Based Discrete Calibrated Survival Prediction. **2022**,
- 282 Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. 0
- 281 A high-throughput drug screen reveals means to differentiate triple-negative breast cancer. 2
- 280 TGFBR3 supports anoikis through suppressing ATF4 signaling.

- 279 SUPREME: A cancer subtype prediction methodology integrating multiomics data using Graph Convolutional Neural Network. 0
- 278 Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer. 1
- 277 Prevalence of Estrogen Receptor Alpha (ESR1) Somatic Mutations in Breast Cancer.
- 276 CD39 + tissue-resident memory CD8 + T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. **2022**, 7, 2
- 275 Integration of multi-omics data shows downregulation of mismatch repair, purin, and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
- 274 Early triple negative breast cancers in a Singapore cohort exhibit high PIK3CA mutation rates associated with low PD-L1 expression.
- 273 Breast Cancer-Delivered Exosomal miRNA as Liquid Biopsy Biomarkers for Metastasis Prediction: A Focus on Translational Research with Clinical Applicability. **2022**, 23, 9371 3
- 272 Retrieval-Based Gradient Boosting Decision Trees for Disease Risk Assessment. **2022**,
- 271 MaCroDNA: Accurate integration of single-cell DNA and RNA data for a deeper understanding of tumor heterogeneity.
- 270 TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding.
- 269 Mastering the use of cellular barcoding to explore cancer heterogeneity. 0
- 268 High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
- 267 SurvTRACE. **2022**, 1
- 266 Elevated insulin-like growth factor 2 mRNA binding protein 1 levels predict a poor prognosis in patients with breast carcinoma using an integrated multi-omics data analysis. 13,
- 265 SetSequence & SetOmic: Deep Set Transformer-based Representations of Cancer Multi-Omics. **2022**,
- 264 Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets. **2022**, 22,
- 263 Triple negative breast cancer: Pitfalls and progress. **2022**, 8, 8
- 262 DNA Methyltransferase 3B Mediated Intratumoral Heterogeneity and Therapeutic Targeting in Breast Cancer Recurrence and Metastasis. OF1-OF12

261	The cross-talk of cancer-associated fibroblasts assist in prognosis and immunotherapy in patients with breast carcinoma.	0
260	Dissecting the contributions of tumor heterogeneity on metastasis at single-cell resolution.	0
259	Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. 2022 , 13,	
258	A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.	0
257	A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.	1
256	Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression.	1
255	Glycosylation defects, offset by PEPCCK-M, drive entosis in breast carcinoma cells. 2022 , 13,	
254	Discovering Significant Patterns under Sequential False Discovery Control. 2022 ,	0
253	DNA methylation as a mediator of genetic and environmental influences on Parkinson's disease susceptibility: Impacts of alpha-Synuclein, physical activity, and pesticide exposure on the epigenome. 13,	2
252	Targeting the mTOR Pathway for the Prevention of ER-negative Breast Cancer.	1
251	A spatial attention guided deep learning system for prediction of pathological complete response using breast cancer histopathology images.	0
250	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer's Review of Molecular Characterisation, Therapeutic Targets and Future Trends. 12,	3
249	Loss of genes in chromosome arms 5q and 16q in breast cancer. 2022 , 41, 331-341	
248	CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner. 2022 , 23, 9314	1
247	Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors. 2022 , 61,	
246	Explaining a series of models by propagating Shapley values. 2022 , 13,	1
245	The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer. 2022 , 1868, 166515	0
244	Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. 2022 , 25, 101511	

- 243 Quantification of ferroptosis pathway status revealed heterogeneity in breast cancer patients with distinct immune microenvironment. 12, ○
- 242 Suppression of OCT-1 in Metastatic Breast Cancer Cells Reduces Tumor Metastatic Potential, Hypoxia Resistance, and Drug Resistance. **2022**, 12, 1435 ○
- 241 General Strategies for Rational Design and Discovery of Multitarget Drugs. **2022**, 677-736 ○
- 240 DCD-chip designed for the digital and ultraprecise quantification of copy number variation. **2022**, 147, 4371-4378 ○
- 239 Proposal of SVM Utility Kernel for Breast Cancer Survival Estimation. **2022**, 1-12 ○
- 238 Bio-interfacial DNA self-assemblies for biomedical applications. **2022**, 259-273 ○
- 237 Complexity and Integration. **2022**, 65-88 ○
- 236 Horizontal Integration: Disease [Cancer Systems Biology. **2022**, ○
- 235 Sharing Time-to-Event Data with Privacy Protection. **2022**, ○
- 234 Mitigating Membership Inference in Deep Learning Applications with High Dimensional Genomic Data. **2022**, ○
- 233 Survival Analysis on Relapse Predictions of Breast Cancer using Optimized ANN and DeepSurv Model. **2022**, ○
- 232 Cancer Subtyping via Embedded Unsupervised Learning on Transcriptomics Data. **2022**, ○
- 231 Development and testing of a polygenic risk score for breast cancer aggressiveness. ○
- 230 Chromatin Variants Reveal the Genetic Determinants of Oncogenesis in Breast Cancer. **2022**, 12, a041322 ○
- 229 ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin. **2022**, 8, ○
- 228 Single-cell and spatial transcriptome analyses revealed cell heterogeneity and immune environment alternations in metastatic axillary lymph nodes in breast cancer. 1
- 227 HSSG: Identification of Cancer Subtypes Based on Heterogeneity Score of A Single Gene. **2022**, 11, 2456 ○
- 226 ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. **2022**, 40, 111268 ○

225	Precision Oncology: An Ensembled Machine Learning Approach to Identify a Candidate mRNA Panel for Stratification of Patients with Breast Cancer. 2022 , 26, 504-511	0
224	MOAHIT: a web tool for visualizing tumor multi-omics data with human anatomy heatmaps.	0
223	GNOSIS: an R Shiny app supporting cancer genomics survival analysis with cBioPortal. 5, 8	0
222	The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. 2022 , 39,	0
221	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. 2022 , 41,	4
220	Attention-based GCN Integrates Multi-omics Data for Breast Cancer Subtype Classification and Patient-specific Gene Marker Identification.	0
219	AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status. 2022 , 23, 11468	0
218	Genomics to select treatment for patients with metastatic breast cancer.	1
217	Molecular Classification of Breast Cancer. 2022 ,	0
216	Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect. 13,	0
215	Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. 13,	0
214	Circ-TRIO promotes TNBC progression by regulating the miR-432-5p/CCDC58 axis. 2022 , 13,	0
213	RNA-based classification of homologous recombination deficiency in racially-diverse patients with breast cancer.	0
212	Causal discovery in high-dimensional, multicollinear datasets. 2,	0
211	IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. 2022 , 39,	0
210	Computational approaches for predicting variant impact: An overview from resources, principles to applications. 13,	0
209	In vivo CRISPR screen defines Slc25a37 as an organ-specific regulator of antioxidant metabolism in metastasis.	0
208	DDR2 coordinates EMT and metabolic reprogramming as a shared effector of FOXQ1 and SNAI1.	0

207	A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers. 2022 , 9,	0
206	Aberrant phosphorylation inactivates Numb in breast cancer causing expansion of the stem cell pool. 2022 , 221,	0
205	Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. 4,	0
204	Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.	0
203	ERK activation modulates invasiveness and Reactive Oxygen Species (ROS) production in triple negative breast cancer cell lines. 2022 , 110487	0
202	A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer. 2022 , 11,	0
201	Machine Learning Methods for Survival Analysis with Clinical and Transcriptomics Data of Breast Cancer. 2023 , 325-393	1
200	UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress. 2022 , 4,	1
199	Cyclin-dependent kinase subunit2 (CKS2) promotes malignant phenotypes and epithelial-mesenchymal transition-like process in glioma by activating TGF β /SMAD signaling.	0
198	NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. 2022 , 22,	1
197	Cyclin B1 expression as an independent prognostic factor for lung adenocarcinoma and its potential pathways. 2022 , 24,	1
196	The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. 12,	0
195	Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer. 2022 , 8498-8567	0
194	An allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function.	0
193	Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.	2
192	An Analysis of Transcriptomic Burden Identifies Biological Progression Roadmaps for Hematological Malignancies and Solid Tumors. 2022 , 10, 2720	0
191	Hypoxia and ER β transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer. 2022 , 14, 4934	0
190	STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential.	0

189	Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology. 9,	1
188	A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.	0
187	Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.	0
186	Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer. 2022 , 12, 1556	0
185	PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer.	0
184	Learning to distinguish progressive and non-progressive ductal carcinoma in situ.	0
183	The maximum entropy principle for compositional data. 2022 , 23,	0
182	Single-cell genomic variation induced by mutational processes in cancer.	3
181	The Predictive and Prognostic Role of RAS/RAF/MEK/ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. 2022 , 14, 5306	0
180	Tumor-educated Gr1 ⁺ CD11b ⁺ cells instigate breast cancer metastasis by twisting cancer cells plasticity via OSM/IL6/JAK signaling.	0
179	Global DNA Methylation Analysis of Cancer-Associated Fibroblasts Reveals Extensive Epigenetic Rewiring Linked with RUNX1 Upregulation in Breast Cancer Stroma. OF1-OF14	2
178	14-3-3 σ drives estrogen receptor loss via ER β 6 induction and GATA3 inhibition in breast cancer. 2022 , 119,	0
177	Predicting clinical response to everolimus in ER ⁺ breast cancers using machine-learning. 9,	0
176	Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma IDH Wildtype. 2022 , 14, 5227	0
175	Explainable AI for clinical and remote health applications: a survey on tabular and time series data.	1
174	Deep learning approach for cancer subtype classification using high-dimensional gene expression data. 2022 , 23,	0
173	A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer.	0
172	Systems Biology and Genomics. 1-11	0

171	A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation.	0
170	Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer. 2022 , 23, 12747	0
169	Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. 2022 ,	1
168	Recent Advances on Penalized Regression Models for Biological Data. 2022 , 10, 3695	0
167	Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. 12,	0
166	Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer. 13,	0
165	A novel ferroptosis-related gene signature for overall survival prediction and immune infiltration in patients with breast cancer. 2022 , 61,	0
164	A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients. 2022 , 23, 13322	0
163	Unique ESR1 and ESR2 estrogen receptor gene variants associated with altered risk of triple-negative breast cancer: A case-control study. 2023 , 851, 146969	0
162	Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer. 2022 , 14, 5643	0
161	Androgen receptor function and targeted therapeutics across breast cancer subtypes. 2022 , 24,	2
160	MLSP: A Bioinformatics Tool for Predicting Molecular Subtypes and Prognosis in Patients with Breast Cancer. 2022 ,	0
159	DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. 2022 , 13,	0
158	Loss of transcription factor TFEB dysregulates the G1/S transition and DNA replication in mammary epithelial cells. 2022 , 102692	0
157	Single-cell imaging based prognosis prediction identifies new breast cancer survival subtypes.	0
156	Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. 2022 , 8,	1
155	Identification of a minority population of LMO2 + breast cancer cells that integrate into the vasculature and initiate metastasis. 2022 , 8,	0
154	Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. 2022 ,	0

- 153 Tumor proliferation and invasion are coupled through cell-extracellular matrix friction. ○
- 152 ViLoNet multi-layer network approach to data integration demonstrated for patient stratification. ○
- 151 Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. **2022**, 14, 5668 1
- 150 Sex steroid hormones and DNA repair regulation: Implications on cancer treatment responses. **2023**, 227, 106230 ○
- 149 Syndecan-4 regulates the HER2-positive breast cancer cell proliferation cells via CK19/AKT signalling. **2023**, 207, 49-61 ○
- 148 Invasive Lobular Carcinoma. **2022**, 655-690 ○
- 147 Feature selection methods for high-dimensional biomedical time-to-event data: a review. **2022**, ○
- 146 Evaluation of Quantification and Normalization Strategies for Phosphoprotein Phosphatase Affinity Proteomics: Application to Breast Cancer Signaling. ○
- 145 PDLIM2 is highly expressed in Breast Cancer tumour-associated macrophages and is required for M2 macrophage polarization. 12, ○
- 144 Exploring the Role of the Inhibitor of Apoptosis BIRC6 in Breast Cancer: A Database Analysis. **2022**, ○
- 143 Understanding and harnessing triple-negative breast cancer-related microbiota in oncology. 12, ○
- 142 Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. 13, ○
- 141 Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer. 13, ○
- 140 Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers. **2022**, 50, 12131-12148 ○
- 139 The Revelation of Continuously Organized, Co-Overexpressed Protein-Coding Genes with Roles in Cellular Communications in Breast Cancer. **2022**, 11, 3806 1
- 138 ERK MAP Kinase Signaling Regulates RAR Signaling to Confer Retinoid Resistance on Breast Cancer Cells. **2022**, 14, 5890 ○
- 137 Synthetic lethality between CCNE1 hyperactivity and PARG inhibition in breast cancer. ○
- 136 The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development. ○

- 135 SETD7 Expression Is Associated with Breast Cancer Survival Outcomes for Specific Molecular Subtypes: A Systematic Analysis of Publicly Available Datasets. **2022**, 14, 6029 ○
- 134 Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. **2022**, 13, ○ 1
- 133 Ethnic and racial-specific differences in levels of centrosome-associated mitotic kinases, proliferative and epithelial-to-mesenchymal markers in breast cancers. **2022**, 17, ○
- 132 DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors and prognostic value relevant to triple-negative breast cancer patients. ○ 1
- 131 NF1 deficiency accelerates mammary development and promotes luminal-basal plasticity. ○
- 130 CMTM7 recognizes an immune-hot tumor microenvironment and predicts therapeutic response of immunotherapy in breast cancer well. 13, ○
- 129 Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis. **2022**, 22, ○
- 128 ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer. **2023**, 12, ○
- 127 Update on triple-negative breast cancers [highlighting subtyping update and treatment implication. **2023**, 82, 17-35 ○ 2
- 126 An integrated analysis of the cancer genome atlas data discovers a hierarchical association structure across thirty three cancer types. **2022**, 1, e0000151 ○
- 125 Breast tumor IGF1R regulates cell adhesion and metastasis: alignment of mouse single cell and human breast cancer transcriptomics. 12, ○
- 124 AKTIP loss is enriched in ER⁺ positive breast cancer for tumorigenesis and confers endocrine resistance. **2022**, 41, 111821 ○
- 123 Radiosensitivity is associated with antitumor immunity in estrogen receptor-negative breast cancer. ○
- 122 Mre11 liberates cGAS from nucleosome sequestration during tumorigenesis. ○
- 121 Incorporating RNA-based risk scores for genomic instability to predict breast cancer recurrence and immunogenicity in a diverse population. ○
- 120 RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients. 12, ○
- 119 High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach. ○
- 118 Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference. **2022**, 14, 6213 ○

- 117 An update on the pathological classification of breast cancer. **2023**, 82, 5-16 1
- 116 MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. 0
- 115 ELOVL5 and IGFBP6 genes modulate sensitivity of breast cancer cells to ferroptosis. 10, 0
- 114 Conventional to Nanotherapeutic Strategies against Triple-Negative Breast Cancer. **2022**, 219-238 0
- 113 Breast cancer heterogeneity and its implication in personalized precision therapy. **2023**, 12, 0
- 112 Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. **2023**, 15, 403 0
- 111 VSOLassoBag: a variable-selection oriented LASSO bagging algorithm for biomarker discovery in omic-based translational research. **2023**, 0
- 110 Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies. **2023**, 11, 238 0
- 109 Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy. 13, 0
- 108 Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. **2023**, 12, 411 0
- 107 CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. **2023**, 22, 0
- 106 The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer. 13, 0
- 105 Learning from small medical data: a robust semi-supervised cancer prognosis classifier with Bayesian variational autoencoder. **2023**, 3, 0
- 104 Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts. 0
- 103 Molecular Sub-Typing and Exploration of Key Signalling Pathways Involved in Complicating the Disease. **2023**, 47-72 0
- 102 Synthetic cell-penetrating RAS-binding peptide for the treatment of KRAS-mutated cancer. 0
- 101 MYC enhancer invasion promotes prognostic cancer type-specific gene programs through an epigenetic switch. 0
- 100 AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells. 26, 0

- 99 ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). **2023**, 19, e1010563 0
- 98 A survey on multi-omics-based cancer diagnosis using machine learning with the potential application in gastrointestinal cancer. 9, 1
- 97 Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression. **2023**, 100056 0
- 96 Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvment of Breast Cancer during Early Dissemination. 2205395 0
- 95 The metabolic enzyme EXT1 is sufficient to induce the epithelial-mesenchymal transition program in cancers. 0
- 94 Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family. **2023**, 857, 147179 0
- 93 Functionalized liposomes for targeted breast cancer drug delivery. **2023**, 24, 401-437 1
- 92 Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures. **2023**, 14, 44 0
- 91 Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. 1
- 90 Sparse canonical correlation to identify breast cancer related genes regulated by copy number aberrations. **2022**, 17, e0276886 1
- 89 Novel Association of IGF2BP2 Gene Variants With Altered Risk of Breast Cancer and as Potential Molecular Biomarker of Triple Negative Breast Cancer. **2022**, 0
- 88 HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. 0
- 87 Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer. **2023**, 14, 0
- 86 Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. **2023**, 0
- 85 MiR-526b targets lncRNA SLC16A1-AS1 to suppress cell proliferation in triple-negative breast cancer. 0
- 84 Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis (BCLM) reveals acquisition of a lobular-like phenotype. 0
- 83 Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment. **2023**, 25, 0
- 82 Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data. **2023**, 12, 367 0

- 81 Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes. **2023**, 11, 10912-10924 ○
- 80 The Tumorigenic Effect of the High Expression of Ladinin-1 in Lung Adenocarcinoma and Its Potential as a Therapeutic Target. **2023**, 28, 1103 ○
- 79 G-quadruplex DNA structures mediate non-autonomous instruction of breast tumour microenvironments. ○
- 78 Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial. ○
- 77 GRHL2-controlled gene expression networks in luminal breast cancer. **2023**, 21, ○
- 76 Distinct tumor architectures for metastatic colonization of the brain. ○
- 75 Ivermectin Induces Oxidative Stress and DNA Damage in Breast Cancer Cells. **2023**, 11, 15-22 ○
- 74 CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer. **2023**, 14, ○
- 73 An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells. **2023**, 649, 1-9 ○
- 72 Utility of proteomics and phosphoproteomics in the tailored medication of cancer. **2023**, 319-332 ○
- 71 Identification and characterization of a proliferative cell population in estrogen receptor-positive metastatic breast cancer through spatial and single-cell transcriptomics. ○
- 70 A comparative analysis of clinicopathological features and survival between pre and postmenopausal breast cancer from an Indian cohort. **2023**, 13, ○
- 69 Deciphering breast cancer: from biology to the clinic. **2023**, 186, 1708-1728 ○
- 68 Prognostic impact of serum vascular endothelial growth factor and VEGF gene polymorphism (rs2010963) in breast cancer patients. **2023**, 36, 201168 ○
- 67 Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients. **2023**, 159, 106866 ○
- 66 TRAF6 as a potential target in advanced breast cancer: a systematic review, meta-analysis, and bioinformatics validation. **2023**, 13, ○
- 65 Fibronectin, DHPS and SLC3A2 Signaling Cooperate to Control Tumor Spheroid Growth, Subcellular eIF5A1/2 Distribution and CDK4/6 Inhibitor Resistance. ○
- 64 Breast cancer survival analysis agents for clinical decision support. **2023**, 231, 107373 ○

- 63 Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. **2023**, 26, 106064 ○
- 62 Molecular aspects of brain metastases in breast cancer. **2023**, 114, 102521 ○
- 61 Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy-driven Metabolic Reprogramming. **2023**, 3, 281-296 ○
- 60 Deep multimodal graph-based network for survival prediction from highly multiplexed images and patient variables. **2023**, 154, 106576 ○
- 59 EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer. ○
- 58 A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF- κ B signaling. **2023**, 4, 344-364 ○
- 57 Lactate from glycolysis regulates inflammatory macrophage polarization in breast cancer. ○
- 56 Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status. **2023**, 198, 197-205 ○
- 55 Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment. 14, ○
- 54 A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA. ○
- 53 Evaluation and comparison of different breast cancer prognosis scores based on gene expression data. **2023**, 25, ○
- 52 The prognostic value and response to immunotherapy of immunogenic cell death-associated genes in breast cancer. 13, ○
- 51 Chemoresistome Mapping in Individual Breast Cancer Patients Unravels Diversity in Dynamic Transcriptional Adaptation. ○
- 50 E2F1-mediated ectopic expression of PP1A promotes breast cancer progression via activation of YAP1. **2023**, 157, 106389 ○
- 49 CD4 T cells and neutrophils contribute to epithelial-mesenchymal transition in breast cancer. ○
- 48 Discovery of multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer. ○
- 47 TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC. ○
- 46 The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness. 14, ○

- 45 Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. **2023**, 41, 585-601.e8
- 44 Deep learning predicts HRD and platinum response from histology slides in breast and ovarian cancer.
- 43 Identification of Cancer Driver Genes by Integrating Multiomics Data with Graph Neural Networks. **2023**, 13, 339
- 42 Zinc finger and SCAN domain containing 1, ZSCAN1, is a novel stemness-related tumor suppressor and transcriptional repressor in breast cancer targeting TAZ. 13,
- 41 Mechanisms of Long Non-Coding RNA in Breast Cancer. **2023**, 24, 4538
- 40 Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data. **2022**, 12,
- 39 ANKLE1 cleaves mitochondrial DNA and contributes to cancer risk by promoting apoptosis resistance and metabolic dysregulation. **2023**, 6,
- 38 Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. **2023**, 14,
- 37 Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits. **2023**, 25,
- 36 Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer. **2023**, 13, 457
- 35 Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.
- 34 Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer. **2023**, 335-353
- 33 Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
- 32 A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival.
- 31 RANK is a poor prognosis marker and a therapeutic target in ER -negative postmenopausal breast cancer. **2023**, 15,
- 30 Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer. **2023**, 21,
- 29 Fluorouracil exacerbates alpha-crystallin B chain-mediated cell migration in triple-negative breast cancer cell lines. **2023**, 13,
- 28 The Novel Phosphatase NUDT5 is a Critical Regulator of Triple-Negative Breast Cancer Growth.

- 27 Improving the robustness and stability of a machine learning model for breast cancer prognosis through the use of multi-modal classifiers. **2023**, 13, ○
- 26 Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. **2023**, 15, 938 ○
- 25 A positive feedback loop driven by fibronectin and IL-1 β sustains the inflammatory microenvironment in breast cancer. **2023**, 25, ○
- 24 A Hybrid Deep Learning Framework with Decision-Level Fusion for Breast Cancer Survival Prediction. **2023**, 7, 50 ○
- 23 Statistical Methods for Integrative Clustering of Multi-omics Data. **2023**, 73-93 ○
- 22 Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. ○
- 21 Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. ○
- 20 Pathology and Somatic Alterations in Hereditary Lobular Breast Cancers. **2023**, 167-180 ○
- 19 Epigenetic Silencing of LRP2 Is Associated with Dedifferentiation and Poor Survival in Multiple Solid Tumor Types. **2023**, 15, 1830 ○
- 18 A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease. ○
- 17 Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment. **2023**, 8, 12217-12231 ○
- 16 Survival analysis of breast cancer patients using machine learning models. ○
- 15 Integration of multi-omics data reveals a novel hybrid breast cancer subtype and its biomarkers. 13, ○
- 14 Immune microenvironment and clinical feature analyses based on a prognostic model in lymph node-positive breast cancer. 13, ○
- 13 Supervised Machine Learning for Breast Cancer Risk Factors Analysis and Survival Prediction. **2023**, 59-71 ○
- 12 Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity. ○
- 11 The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure \square A computational approach. 1-14 ○
- 10 RAS-induced transformation of mammary epithelial cells relies on ZEB1-dependent cellular reprogramming via a paracrine process. ○

- 9 Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis. **2023**, 15, 175883592311659
- 8 Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.
- 7 Methylglyoxal: a novel upstream regulator of DNA methylation. **2023**, 42,
- 6 N-acetylcysteine overcomes NF1 loss-driven resistance to PI3K inhibition in breast cancer. **2023**, 4, 101002
- 5 Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers.
- 4 The genomic and evolutionary landscapes of anaplastic thyroid carcinoma.
- 3 How valuable can proteogenomics be in clinical breast cancer research?. 1-4
- 2 Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses. **2023**, 15, 2393
- 1 XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes. **2023**, 84, 104979